

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
12 April 2007 (12.04.2007)

PCT

(10) International Publication Number
WO 2007/039113 A1(51) International Patent Classification:
A61K 31/05 (2006.01) **A6IP 11/00** (2006.01)

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(21) International Application Number:
PCT/EP2006/009154(22) International Filing Date:
20 September 2006 (20.09.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
05020510.3 20 September 2005 (20.09.2005) EP(71) Applicant (for all designated States except US):
REVOTAR BIOPHARMACEUTICALS AG [DE/DE]
Neuendorfstrasse 24a, 16761 Hennigsdorf (DE).

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).





(72) Inventors; and

(75) Inventors/Applicants (for US only): **AYDT, Ewald** [DE/DE]; Lloyd-G. Wells-Strasse 20, 14163 Berlin (DE). **KRANICH, Remo** [DE/DE]; Hennigsdorfer Str. 141N, 13503 Berlin (DE). **BUSEMANN, Anke** [DE/DE]; Ringpromenade 24, 16761 Hennigsdorf (DE).(74) Agent: **ISENBRUCK, Günter**; Isenbruck Bösl Hörschler Wichmann Huhn, Theodor-Heuss-Anlage 12, 68165 Mannheim (DE).**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NOVEL AROMATIC COMPOUNDS AND THEIR USE IN MEDICAL APPLICATIONS



(57) Abstract: Pharmaceutical compositions comprising at least one compound of the formulas (Ia) or (Ib) and a pharmaceutically acceptable carrier wherein the symbols have the following meaning -X- is e.g. and Y being e.g. or the pharmaceutically acceptable salts can be applied to modulate the in-vitro and in-vivo binding processes mediated by E-, P- or L-selectin binding.

Novel aromatic compounds and their use in medical applications

5

The present invention relates to compounds, compositions and methods for modulating the *in vitro* and *in vivo* processes mediated by cell adhesion molecules. The disclosed small molecules comprise trimethoxy phenyl subunits and modulate cell adhesion molecule-mediated functions potently.

Cell-adhesion molecule-mediated functions are part of a complex cascade leading to the migration of circulating white blood cells (leukocytes) from the blood stream into the surrounding tissue (transmigration). Physiologically, leukocyte transmigration is of critical importance for homeostasis and immuno-surveillance of living beings including humans. Lymphocytes for example, are constitutively leaving the blood stream into lymphatic tissues in order to patrol for harmful antigens. Under pathological circumstances however, e.g. local or systemic inflammation and/or injury of the vascular system, this fundamental process is dys-regulated, at least in part, due to an increased surface expression of E- and P-selectin. Consequently, the excessive leukocyte transmigration leads to a pathological cellular infiltrate with subsequent tissue damage in several clinically relevant settings. Disease states such as Acute Lung Injury (ALI), Acute Respiratory Distress Syndrome (ARDS), Asthma bronchiale (asthma), Chronic Obstructive Pulmonary Disease (COPD), Psoriasis, Rheumatoid Arthritis, and Sepsis are all associated with tissue inflammation induced and perpetuated by pathologically activated leukocytes infiltrating the respective tissue. In addition, exaggerated leukocyte infiltration contributes to the pathogenesis of Ischemic-Reperfusion Injury (IRI) associated with organ transplantation, cardiopulmonary bypass or percutaneous transluminal angioplasty.

To transmigrate, leukocytes must bind to the wall of the vascular endothelium to diffuse through the cell wall of the capillary into the surrounding tissue. Therefore, leukocytes

have to roll onto and then adhere to the endothelial cell wall (initial rolling or "tethering"). This primary event in transmigration is mediated by the selectin family of cell-adhesion molecules. In addition to directly binding to the endothelium, leukocytes can adhere to other leukocytes, leukocyte- particles, platelets or platelet-derived particles that are already
5 attached to the endothelium.

The selectin family of adhesion molecules is comprised of three structurally related calcium-dependent carbohydrate binding cell surface proteins, E-, P- and L-selectin. E-selectin is expressed only on inflamed endothelium, P-selectin is expressed on inflamed
10 endothelium as well as on platelets and L-selectin is expressed on leukocytes. Selectins are composed of an amino terminal lectin domain, an epidermal growth factor (EGF)-like domain, a variable number of complement receptor-related repeats, a hydrophobic transmembrane domain and a C-terminal cytoplasmic domain. The binding interactions leading to the adhesion of the leukocytes are supposed to be mediated by contact of the
15 lectin domain of the selectins and various carbohydrate ligands on the surface of the leukocytes. All three selectins can bind with low affinity to the carbohydrate sialyl Lewis^x (sLe^x), a glycosyl moiety present on the surface of most leukocytes. A structurally related glycosyl moiety, sialyl Lewis^a (sLe^a), is predominantly found on the surface of cancer cells [K. Okazaki et al., *J. Surg. Res.*, 1998, 78(1), 78-84; R. P. McEver et al., *Glycoconjugate Journal*, 1997, 14(5), 585-591]. In case of P-selectin, a distinct high affinity glycoprotein
20 ligand has been described [R.P. McEver, R.D. Cummings, *J.Clin.Invest.*, 1997, 100, 485-492], the so-called P-selectin glycoprotein ligand-1 (PSGL-1), which contributes to a high affinity selectin binding by its sLe^x moiety as well as by parts of its peptide components, in particular sulphated tyrosine residues [R.P. McEver, *Ernst Schering Res. Found. Workshop*, 2004, 44, 137-147]. PSGL-1 is one of the most important selectin ligands binding with highest affinity to P-selectin, but it also binds to E- and L-selectin [G.
25 Constantin; *Drug News Perspect*; 2004; 17(9); 579-586]. It is a homodimeric sialomucin predominantly expressed on leukocytes.

30 In inflammatory diseases, dys-regulated transmigration is, at least in part, mediated due to an increased cell surface expression of E- and P-selectin. In contrast to their low basal expression, E- and P-selectin expression is upregulated during inflammation, leading to a

substantial recruitment of leukocytes into the inflamed tissue. Although selectin-mediated cell adhesion is required for fighting infection, there are various situations in which such cell adhesion is undesirable or excessive, resulting in severe tissue damage instead of repair. In the case of many acute as well as chronic inflammatory disorders [e.g., asthma, 5 chronic obstructive pulmonary disease (COPD), psoriasis, etc.], an association between infiltration of activated leukocytes into the tissue simultaneously with a marked elevation of tissue expression of corresponding adhesion molecules, particularly E- and P-selectin, has been demonstrated [Muller et al., *J. Pathol.*, 2002, 198(2), 270-275; Di Stefano et al., 10 *Am. J. Respir. Crit. Care. Med.*, 1994, 149(3) 803-810; Terajima et al., *Arch. Dermatol. Res.*, 1998, 290, 246-252]

Leukocyte infiltration may also play a role in inflammatory symptoms in the course of transplant and graft rejection. Also the process of blood clotting is further promoted by leukocyte-leukocyte and leukocyte-platelet binding, which occurs because leukocytes 15 possess both L-selectin and its corresponding ligand PSGL-1 and can thus interact with themselves via PSGL-1, and they can also bind to platelets which carry P-selectin.

Therefore, the modulation of selectin-mediated cell adhesion and other selectin mediated functions, e.g. leukocyte activation, offers a promising possibility to interfere with and stop 20 the inflammation cascade at a very early step. Small molecule selectin antagonists should modulate all three selectins simultaneously as pan-selectin-antagonists to circumvent possible redundancies between the selectins [M. Sperandio et al., *Vascular Disease Prevention*, 2004, 1, 185-195].

25 Besides sLe^x/sLe^a, the natural, high affinity ligand PSGL-1 is another template structure for the design of small molecule selectin antagonists. As compared to sLe^x/sLe^a, PSGL-1 shows high affinity for all three selectins. To find and to detect novel small molecule drugs that compete with PSGL-1 and PSGL-1-like ligands for selectin binding is therefore a promising strategy to develop a novel class of effective pan-selectin antagonists for 30 treating inflammatory disorders. Selectin antagonists may be designed using selectins as well as using a ligand like PSGL-1 as a template structure, since they are intended to

modulate the binding between selectins and PSGL-1 or other ligands with similar binding motifs.

Novel small molecule selectin antagonists could meet certain requirements to be drug-like
5 and to have potential oral bioavailability. The term drug likeness is described in the literature [Lipinski; *Adv. Drug Dev. Rev.*, 1997, 23, 3-25]. Beside other molecular properties, passively transported molecules are supposed to have on average a relative molecular weight of less than 500 in order to be drug like. According to these rules it is common to define compounds with a relative molecular weight of less 500 or closely
10 above that as small molecules. Compounds with relative molecular weights above 500 are unlikely to be orally bioavailable. Also the presence of highly polar carbohydrate moieties or a peptidic components is not in accordance with the concept of drug likeness [H. Ulbrich et al., *Trends Pharmacol. Sci.*, 2003, 24(12), 640-647; D. Slee et al., *J. Med. Chem.*, 2001, 44, 2094-2107]. The same accounts for the development of antibody-based
15 drugs, because they are polypeptides and so oral administration is a problem. Moreover, the desired compounds must be stable during the passage through the gastrointestinal tract so that they can be ingested/absorbed latest by the cells of the small intestines. This is not the case for most glycosidic molecules and peptidic structures.

20 There have been various investigations to develop low-molecular weight compounds with an modulatory effect on selectin mediated processes. These compounds include disalicylates and disalicylate-based C-glycosides [WO 99/29706], benzyl amino sulfonic acids [WO 03/097658], diglycosylated 1,2-diols [WO 97/01569], substituted 5-membered heterocycles [WO 00/33836], mannopyranosyloxy-phenyl-benzoic acids [EP0758243 B1],
25 piperazine based compounds [US6432957B1], gallic acid derivatives of peptides [WO 2004/018502], gallic acid [C. C. M. Appeldoorn et al., *Circulation* 2005, 111, 106-112; EP 1481669A1], and quinic acid derivatives [N. Kaila et al., *J. Med. Chem.* 2005, 48, 4346-4357]. However, none of these selectin-antagonizing compounds have successfully passed clinical trials up to date [S. J. Romano, *Treat. Respir Med* 2005, 4(2), 85-94; M. P. Schön,
30 *Therapeutics and Clinical Risk Management*, 2005, 1(3), 201-208]. This is due to the fact, that many of these structures have been designed on the basis of the low potency template sLe^X. Therefore, sLe^X-mimicking structures are likely to show low potency. Other

- 5 -

compounds show specificity against different members of the selectin family, but antagonizing only selected selectins can be bypassed by other selectins [M. P. Schön, *Therapeutics and Clinical Risk Management*, 2005, 1(3), 201-208]. In addition, most of the compounds developed so far have high molecular weights and often bear carbohydrates and/or peptides making them prone to degradation and modification by peptidases and/or glycosidases. Carbohydrate-bearing structures have further disadvantages such as high degree of chirality, anomericity, and low probability of transport through lipid bilayers. Similar disadvantages are known for peptide-bearing compounds. Some other compounds developed for antagonizing selectin mediated processes contain pyrogallol- and catechol-substructures. These motifs are prone to oxidation processes [Kumamoto M. et al., *Biosci. Biotechnol. Biochem.*, 2001, 65(1), 126-132] making the pharmaceutical development of these compounds difficult. In addition, compounds with pyrogallol substructures, such as gallic acid, are known to be cytotoxic [E. Sergediene et al., *FEBS Letters*, 1999, 462, 392-396] and induce apoptosis [K. Satoh et al., *Anticancer Research*, 1997, 17, 2487-2490; N. Sakaguchi et al., *Biochemical Pharmacology*, 1998, 55, 1973-1981].

The leading compound in the field of selectin antagonists is bimosiamose [S. J. Romano, *Treat. Respir Med* 2005, 4(2), 85-94]. Presently bimosiamose [D. Bock et al., *New Drugs*, 2003, D04, 28, p.28; EP 0 840 606 B1] is the most advanced compound in clinical studies. Recent investigations support the hypothesis that bimosiamose can be considered as PSGL-1 mimetic [E. Aydt, G. Wolff; *Pathobiology*; 2002-2003; 70; 297-301]. This distinguishes bimosiamose from other selectin antagonists. It is, however, a high molecular weight compound with carbohydrate structures. The pan-selectin antagonist bimosiamose seems to lack oral bioavailability. Some observations indicate that bimosiamose shows good affinity for P-selectin and a moderate affinity for E- and L-selectin.

25


There is a strong medical need for novel highly potent pan-selectin antagonists which modulate selectin-mediated function, e.g. of selectin-dependent cell adhesion, and for the development of methods employing such compounds to modulate conditions associated with selectin-ligand interaction. Most of the available anti-inflammatory pharmaceutical therapies, which are available on the market, comprise mostly corticosteroids or NSAIDs (non steroid anti-inflammatory drugs) having several serious drawbacks/side effects, and target different steps of the inflammatory cascade. Unlike this, modulating the selectin

function is a therapeutic concept intervening the inflammation cascade at a very early stage. Almost all promising selectin antagonists so far failed to become marketed drugs, mostly because of low potency and /or high molecular weight that causes problems in their absorption-distribution-metabolism-excretion (ADME) behaviour and thus in oral 5 bioavailability required for the treatment of most inflammatory disorders like rheumatoid arthritis, septic shock, atherosclerosis, reperfusion injury and many others.

Object of the invention is to provide novel small molecules, especially non-glycosylated/non-glycosidic and non-peptidic compounds, which are able to potently 10 antagonize selectin-mediated processes and which have less negative side effects during their application than prior art compounds.

Unlike most of the sLe^X-mimicking compounds developed in this field, the inventive 15 compounds are not prone to glycosidases or peptidases. Most of the selectin antagonists developed so far are structurally and biologically based on the properties of sLe^X or sLe^a. These resulting compounds showed, therefore, low biological activity like their template structures. This invention, however, provides novel potent small and drug like pan-selectin 20 antagonists that have been invented on the basis of biological in vitro assays mimicking PSGL-1 and PSGL-1-like ligands or any ligands bearing sLe^X or sLe^a and tyrosinesulfate motifs [N. V. Bovin; *Biochem Soc Symp.*; 2002;(69):143-60. N. V. Bovin; *Glycoconj. J.*; 1998; 15(5); 431-46. T.V. Pochechueva et al.; *Bioorg Med Chem Lett.*; 2003;13(10);1709-20 12. G. Weitz-Schmidt et al.; *Anal. Biochem.*;1996; 238; 184-190].

The present invention provides pharmaceutical compositions comprising at least one 25 compound having the general structure of formulas (Ia) or (Ib) and a pharmaceutically acceptable carrier which is useful in medicine.




wherein the symbols and substituents have the following meaning

- 7 -


 $-X-$ =

(a)


with $m = 0, 1$; $n = \text{an integer from } 1 \text{ to } 3$

5


(b)



wherein "ring" is

and with R^1 being H , NO_2 , CF_3 , F , Cl , Br , I , CN , CH_3 , NH_2 , $NHAlkyl$, $NHAryl$, $NHAcyl$ and $k = 0, 1$

(c)



15

 T being O , S or $[H,H]$; $p = 0, 1, 2$,


- 8 -

(d)




the double bond is either *E*- or *Z*-configurated

(e)



5

(f)




with $-E-$ being $-(CH_2)_qNH-$ and $q = 0, 1, 2, 3$

$-Y =$

10

(a)



with s being 0 or 1,

- 9 -

R^2 being CO_2H , CO_2Alkyl , CO_2Aryl , CO_2NH_2 , $CO_2Aralkyl$, SO_3H , SO_2NH_2 , $PO(OH)_2$, 1-H-tetrazolyl-, CHO, COCH₃, CH₂OH, NH₂, NHAlkyl, N(Alkyl)Alkyl', OCH₃, CH₂OCH₃, SH, F, Cl, Br, I, CH₃, CH₂CH₃, CN, CF₃

R^3 independently from R^2 being H, CH₃, CH₂CH₃, CF₃, F, Cl, Br, I, CN, NO₂ and


5 R^4 independently from R^2 and R^3 being H, CH₃, CH₂CH₃, CF₃, F, Cl, Br, I, CN, NO₂, R²

R^5 being H, NO₂, CF₃, F, Cl, Br, I, CN, CH₃, OCH₃, SH, NH₂

and -W- = -(CH₂-)_v, *cis*-CH=CH- or *trans*-CH=CH-, and v being 0,1,2;


in case that -W- is *cis*-CH=CH- or *trans*-CH=CH-, R^2 must not be NH₂ or SH;

10 (b)




R^6 independently from R^2 being H, F, Cl, Me, tert-Bu, CN, NH₂

(c)




15

(d)



(e)




20


- 10 -

with t being 0,1,2

(f)




(g)



5


-Z =

(i)




10 R⁷ independently from R² being H, NO₂, CF₃, F, Cl, Br, I, CN, CH₃, OCH₃, SH, NH₂,

(ii)



15 R⁸ independently from R² being H, F, Cl, Me, tert-Bu, CN, NH₂

(iii)



- 11 -


(iv)




with K = NH, NMe, O, S

5

(v)



(vi)




(vii)

10 -W-R²

or the pharmaceutically acceptable salts, esters or amides and prodrugs of the above identified compounds of formulas (Ia) or (Ib).

15 In a preferred embodiment of the invention, the compositions comprise a compound of the formulas (Ia) or (Ib) and a pharmaceutically acceptable carrier which is useful in a medicine,




- 12 -

wherein the symbols, indices and substituents have the following meaning


-X- =

(a)




5 with m = 0,1; n = an integer from 1 to 3

(b)




10 wherein "ring" is



and with R¹ being H, NO₂, CF₃, F, Cl, Br, I, CN, CH₃, NH₂, NHAlkyl, NHArlyl, NHAcyl and k = 0,1

15 (c)




T being O, S or [H,H]; p = 0,1,2,

-Y =

- 13 -

(a)



with s being 0 or 1,

R² being CO₂H, CO₂Alkyl, CO₂Aryl, CO₂NH₂, CO₂Aralkyl, SO₃H, SO₂NH₂, PO(OH)₂, 1-H-tetrazolyl-, CHO, COCH₃, CH₂OH, NH₂, NHAlkyl, N(Alkyl)Alkyl', OCH₃, CH₂OCH₃, SH, F, Cl, Br, I, CH₃, CH₂CH₃, CN, CF₃

R³ independently from R² being H, CH₃, CH₂CH₃, CF₃, F, Cl, Br, I, CN, NO₂ and


R⁴ independently from R² and R³ being H, CH₃, CH₂CH₃, CF₃, F, Cl, Br, I, CN, NO₂, R²

R⁵ being H, NO₂, CF₃, F, Cl, Br, I, CN, CH₃, OCH₃, SH, NH₂

and -W- = -(CH₂)_v, *cis*-CH=CH- or *trans*-CH=CH-, and v being 0,1,2;

in case that -W- is *cis*-CH=CH- or *trans*-CH=CH-, R² must not be NH₂ or SH;


(e)



with t being 0,1,2

-Z =

(i)



R⁷ independently from R² being H, NO₂, CF₃, F, Cl, Br, I, CN, CH₃, OCH₃, SH, NH₂,

- 14 -

(iv)




with K = NH, NMe, O, S

5 or the pharmaceutically acceptable salts, esters or amides and prodrugs of the above identified compounds of formulas (Ia) or (Ib).

Preferred pharmaceutical compositions comprise compounds of formulas (IIa) or (IIb)




10



wherein -Y is like defined above and wherein -X'- is X (a), X (b), X (c), and X (d) like defined above. Preferred definitions of -X'- are X(a), X(b) and X(c), more preferred are X(b) and X(c).

15


Further preferred pharmaceutical compositions comprise compounds of formulas (A1), (B1), (A2) or (B2)




20

wherein -X'- and -Y are like defined above and wherein -X''- is

- 15 -




and wherein -Y' is



5 wherein all indices, symbols and substituents are like defined above.


In a further embodiment of the invention, the compounds of the formulas A1, A2, B1 and B2 are used, wherein -X'- and -Y are as defined as above and wherein -X''- is



10



and wherein -Y' is

- 16 -



and wherein all other indices, symbols and substituents are as defined above.



- 5 Particularly preferred pharmaceutical compositions comprise compounds of formulas (C) and (D)



wherein -X''- and -Y' are like defined above.

10


- Very particularly preferred pharmaceutical compositions comprise at least one compound of formulas (E) and (F)



wherein -X''- is like defined above and -Y'' is

15


- 17 -




with R^9 being CO_2H , CO_2alkyl , CO_2aryl , CO_2NH_2 , $\text{CO}_2\text{aralkyl}$, $\text{CH}_2\text{SO}_3\text{H}$, $\text{CH}_2\text{SO}_2\text{NH}_2$, $\text{CH}_2\text{PO}(\text{OH})_2$, 1-H-tetrazolyl, CHO, COCH_3 , CH_2OH , CH_2NH_2 , $\text{CH}_2\text{NHalkyl}$, $\text{CH}_2\text{N(alkyl)alkyl}'$, CH_2OCH_3 , CH_2SH ,

5 wherein the indices, symbols and substituents are defined as above.

The invention also relates to pharmaceutical compositions, wherein the compounds are defined by formulas (E) or (F)



10 wherein $-X''-$ is as defined as above and $-Y''$ is



- 18 -

with R⁹ being CO₂H, CO₂alkyl, CO₂aryl, CO₂NH₂, CO₂aralkyl, CH₂SO₃H, CH₂SO₂NH₂, CH₂PO(OH)₂, 1-H-tetrazolyl, CHO, COCH₃, CH₂OH, CH₂NH₂, CH₂NHalkyl, CH₂N(alkyl)alkyl', CH₂OCH₃, CH₂SH,

5 wherein all other indices, symbols and substituents are as defined above.

These chemical compounds (C), (D), (E) and (F) are also new compounds for themselves.

All compounds as described before present the ability of modulating cell adhesion and
10 modulate selectin- as well as PSGL-1-like mediated binding. The compounds have the
ability to modulate the interaction of selectins with sLe^x/sLe^a and also the interaction
between selectins and tyrosinesulfate residues. Therefore they are useful for the treatment
of acute and chronic inflammatory disorders, as well as other medical conditions where
selectin mediated processes play a role.

15

The term "pharmaceutical" includes also diagnostic applications.

The term "pharmaceutical" includes also prophylactic applications in order to prevent
medical conditions where selectin mediated processes play a role.

The term "pharmaceutical" includes also applications, where compounds of the present
20 invention may be used as vehicles for drug targeting of diagnostics or therapeutics.

The invention provides pharmaceutical compositions comprising compounds of formulas
(Ia) or (Ib) and in a preferred variant of formulas (IIa) or (IIb).

In a further preferred variant the invention provides pharmaceutical compositions
25 comprising at least one compound of formula (A1), (A2), (B1) or (B2).

In a particularly preferred variant the invention provides pharmaceutical compositions
comprising at least one compound of formula (C) or (D).

In a very particularly preferred variant the invention provides pharmaceutical compositions comprising at least one compound of formula (E) or (F).

The present invention further provides a method of modulating the binding of P-selectin, L-selectin or E-selectin to sLe^x or sLe^a and tyrosinesulfate residues comprising the step of administering to a patient an effective amount of at least one compound having the structure of formulas (Ia) or (Ib) to modulate the binding of P-, E- or L-selectin to sLe^x or sLe^a and tyrosinesulfate. It has been found that compounds having the formulas (Ia) or (Ib) shown above act to modulate E-, P- or L-selectin binding.

10

As used herein the terms “alkyl” shall mean a monovalent straight chain or branched chain group of 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 carbon atoms including, but not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl and the like. “Alkyl” is independently from each other and can be different or identical.

15

The term “aryl” shall mean carbocyclic and heterocyclic aromatic groups including, but not limited to, phenyl, 1-naphthyl, 2-naphthyl, fluorenyl, (1,2)-dihydronaphthyl, indenyl, indanyl, thienyl, benzothienyl, thienopyridyl and the like.

20

The term “aralkyl” (also called arylalkyl) shall mean an aryl group appended to an alkyl group including, but not limited to, benzyl, 1-naphthylmethyl, 2-naphthylmethyl, fluorobenzyl, chlorobenzyl, bromobenzyl, iodobenzyl, alkoxybenzyl (wherein “alkoxy” means methoxy, ethoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy and the like), hydroxybenzyl, aminobenzyl, nitrobenzyl, guanidinobenzyl, fluorenylmethyl, phenylmethyl(benzyl), 1-phenylethyl, 2-phenylethyl, 1-naphthylethyl and the like.

25

The term “acyl” shall mean -(CHO) or -(C=O)-alkyl or -(C=O)-aryl or -(C=O)-aralkyl including, but not limited to, formyl, acetyl, n-propionyl, isopropionyl, n-butyryl, isobutyryl, pivaloyl, benzoyl, 4-nitrobenzoyl and the like.

The term "pharmaceutically acceptable salts, esters, amides and prodrugs" as used herein refers to those carboxylate salts, amino acid addition salts, esters, amides and prodrugs of the compounds of the present invention which are, within the scope of sound medical judgment, suitable for use in contact with tissues of patients without undue toxicity, irritation, allergic response and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the present invention. The term "salts" refers to the relatively non-toxic, inorganic and organic acid addition salts of the compounds of the present invention. These salts can be prepared *in situ* during the final isolation and purification of the compounds or by separately reacting the purified compounds in its free form with a suitable inorganic or organic acid or base and isolating the salt thus formed. Representative salts of the compounds of the present invention include the hydrobromide, hydrochloride, sulfate, bisulfate, nitrate, acetate, oxalate, valerate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate, lactobionate, laurylsulphonate salts and the like. These may include cations based on the alkali and alkalineearth metals, such as sodium, lithium, potassium, calcium, magnesium and the like, as well as non-toxic ammonium, quaternary ammonium and amine cations including, but not limited to, ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, and the like.

Examples of the pharmaceutically acceptable, non-toxic esters of the compounds of this invention include C₁, C₂, C₃, C₄, C₅ and C₆ alkyl esters wherein the alkyl group is a straight or branched chain. Acceptable esters also include C₅, C₆ and C₇ cycloalkyl esters as well as arylalkyl esters such as, but not limited to benzyl. C₁, C₂, C₃, C₄, C₅ and C₆ alkyl ester are preferred. Esters of the compounds of the present invention may be prepared according to conventional methods.

Examples of pharmaceutically acceptable, non-toxic amides of compounds of this invention include amides derived from ammonia, primary C₁, C₂, C₃, C₄, C₅ and C₆ alkyl amines and secondary C₁, C₂, C₃, C₄, C₅ and C₆ dialkyl amines wherein the alkyl groups

are straight or branched chains. In the case of secondary amines the amine may also be in the form of a 5 or 6 membered heterocycle containing one nitrogen atom. Amides derived from ammonia, C₁, C₂ and C₃ alkyl primary amides and C₁ to C₂ dialkyl secondary amides are preferred. Amides of the compounds of the present invention may be prepared 5 according to conventional methods.

The term "prodrug" refers to one or more compounds that are rapidly transformed *in vitro* and from a non-active to active state *in vivo* to yield the parent compound of the above formulas (Ia) or (Ib), for example by hydrolysis in blood or *in vivo* metabolism.

10

It is also contemplated that pharmaceutically active compositions may contain a compound of the present invention or other compounds that modulate or compete with E-selectin or P-selectin or L-selectin binding.

15 Pharmaceutically active compositions of the present invention comprise a pharmaceutically acceptable carrier and a compound of formulas (Ia) or (Ib), whereby a pharmaceutically acceptable carrier can also be a medically appropriate nano-particle, dendrimer, liposome, microbubble or polyethylene glycol (PEG). The pharmaceutical compositions of the present invention may include one or more of the compounds having 20 the above structure (Ia) or (Ib) formulated together with one or more, physiologically acceptable carriers, adjuvants or vehicles, which are collectively referred to herein as carriers, for parenteral injection, for oral administration in solid or liquid form, for rectal or topical administration and the like.

25 The compositions can be administered to humans and animals either orally, rectally, parenterally (intravenously, intramuscularly, intradermally or subcutaneously), intracisternally, intravaginally, interperitoneally, locally (powders, ointments or drops), or as a buccal or by inhalation (nebulized, or as nasal sprays).

Compositions suitable for parenteral injection may comprise physiologically acceptable sterile aqueous or nonaqueous solutions, stabilizers, antioxidants, preservatives (e.g. ascorbic acid, sodium sulfite, sodium hydrogencarbonate, benzyl alcohol, EDTA), dispersions, suspensions or emulsions and sterile powders for reconstitution into sterile
5 injectable solution or dispersion. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyol, (propylene glycol, polyethylene glycol, glycerol and the like), suitable mixtures thereof, vegetable oils (such as olive or canola oil) and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for examples, by the use of a coating such as lecithin, by the maintenance
10 of the required particle size in the case of dispersions and by the use of surfactants.

These compositions may also contain adjuvants such as preserving, wetting, emulsifying, and dispersing agents. Prevention of the actions of microorganisms can be ensured by various antibacterial and antifungal agents, for examples, parabens, chlorobutanol, phenol,
15 sorbic acid, and the like. It may also be desirable to include isotonic agents, for examples sugars, sodium chloride and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, for examples aluminium monostearate and gelatin.

20 If desired, and for more effective distribution, the compounds can be incorporated into slow or timed release or targeted delivery systems such as polymer matrices, liposomes, and microspheres. They may be sterilized, for example, by filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile water, or some other sterile injectable medium immediately before use.

25

Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In such solid dosage forms, the active compound or a prodrug is admixed with at least one inert customary excipient (or carrier) such as sodium citrate or dicalcium phosphate or (i) fillers or extenders, as for example, starches, lactose, sucrose, glucose,
30 mannitol and silicic acid, (ii) binders, as for example, carboxymethylcellulose, alginates,

gelatine, polyvinylpyrrolidone, sucrose and acacia, (iii) humectants, as for example, glycerol, (iv) disintegrating agents, as for example, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates and sodium carbonate, (v) solution retarders, as for examples, paraffin, (vi) absorption accelerators, as for example, quaternary ammonium compounds, (vii) wetting agents, as for examples, cetyl alcohol and glycerol monostearate, (viii) adsorbents, as for example, kaolin and bentonite, and (ix) lubricants, as for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate and mixtures thereof. In the case of capsules, tablets, and pills, the dosage forms may also comprise buffering agents.

10

Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatine capsules using excipients as lactose or milk sugars as well as high molecular polyethylene glycols and the like. Solid dosage forms such as tablets, dragées, capsules, pills and granules can be prepared with coatings and shells, such as enteric coatings and others well known in the art. They may contain opacifying agents, and can also be of such compositions that they release the active compound or compounds in a certain part of the intestinal tract in a delayed manner. Examples of embedding compositions that can be used are polymeric substances and waxes. The active compounds can also be in microencapsulated form, if appropriate, with one or more of the above-mentioned 15 excipients.

Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as water or other solvents, solubilizing agents and emulsifiers, as for example, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils, in particular, cottonseed 25 oil, groundnut oil, corn germ oil, olive oil, canola oil, caster oil and sesame seed oil, glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan or mixtures of these substances, and the like. Besides such inert diluents, the compositions 30

can also include adjuvants, such as wetting agents, emulsifying and suspending agents, sweetening, flavouring and perfuming agents.

5 Suspensions, in addition to the active compounds, may contain suspending agents, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminium metahydroxide, bentonite, agar-agar, tragacanth or mixtures of these substances and the like.

10 Compositions for rectal administrations are preferably suppositories, which can be prepared by mixing the compounds of the present invention with suitable nonirritating excipients or carriers such as cacao butter, polyethylene glycol or a suppository wax, which are solid at ordinary temperatures but liquid at body temperature and therefore melt in the rectal or vaginal cavity and release the active component. Dosage forms for topical administration of a compound of this invention include ointments, powder, sprays and
15 inhalants.

The active component is admixed under sterile conditions with a physiologically acceptable carrier and any needed preservatives, buffers or propellants as may be required. Ophthalmic formulations, eye ointments, suspensions, powder and solutions are also contemplated as being within the scope of this invention.

20

The compounds of the present invention can also be incorporated into or connected to liposomes or administrated in the form of liposomes. As is known in the art, liposomes are generally derived from phospholipids or other lipid substances. Liposomes are formed by mono or multilamellar hydrated liquid crystals that are dispersed in an aqueous medium.
25 Any non-toxic, physiologically acceptable metabolized lipid capable of forming liposomes can be used. The present compositions in liposome form can contain, in addition to the selectin binding antagonists of the present invention, stabilizers, preservatives, excipients and the like. The preferred lipids are the phospholipids and the phosphatidyl cholines (lecithins), both natural and synthetic. Methods to form liposomes are well known in the
30 art.

Non-parenteral dosage forms may also contain a bioavailability enhancing agent (e.g. enzyme modulators, antioxidants) appropriate for the protection of the compounds against degradation. Actual dosage levels of active ingredient in the composition of the present invention may be varied so as to obtain an amount of active ingredient that is effective to obtain the desired therapeutic response for a particular composition and method of administration. The selected dosage level, therefore, depends on the desired therapeutic effect, on the route of administration, on the desired duration of treatment and other factors. The total daily dosage of the compounds on this invention administered to a host in single or divided doses may be in the range up to 50 mg per kilogram of body weight. Dosage unit compositions may contain such submultiples thereof as may be used to make up the daily dosage. It will be understood, however, that the specific dose level for any particular patient, whether human or other animal, will depend upon a variety of factors including the body weight, general health, sex diet, time and route of administration, rates of absorption and excretion, combination with other drugs and the severity of the particular disease being treated.

In particular, the compounds of the present invention may be used to treat a variety of diseases relating to inflammation and cell-cell recognition and adhesion. For example, the compounds of the present invention may be administrated to a patient to treat Chronic Obstructive Pulmonary Disease (COPD), acute lung injury (ALI), cardiopulmonary bypass, acute respiratory distress syndrome (ARDS), Crohn's disease, septic shock, sepsis, chronic inflammatory diseases such as psoriasis, atopic dermatitis, and rheumatoid arthritis, and reperfusion injury that occurs following heart attacks, strokes, atherosclerosis, and organ transplants, traumatic shock, multi-organ failure, autoimmune diseases like multiple sclerosis, percutaneous transluminal angioplasty, asthma and inflammatory bowel disease. In each case, an effective amount of the compounds of the present invention is administered either alone or as part of a pharmaceutically active composition to a patient in need of such treatment. It is also recognized that a combination of the compounds may be administered to a patient in need of such administration. The compounds of the present invention may also be administered to treat other diseases that are associated with cell-cell adhesion. As the present compounds modulate the binding of E-selectin or P-selectin or L-

selectin, any disease that is related to this interaction may potentially be treated by the modulation of this binding interaction.

In addition to being found on some white blood cells, sLe^a is found on various cancer cells,
5 including lung and colon cancer cells. It has been suggested that cell adhesion involving
sLe^a may be involved in the metastasis of certain cancers and antagonists of sLe^a binding
might be useful in treatment of some forms of cancer.

The use of the active ingredients according to the invention or of cosmetic or topical
10 dermatological compositions with an effective content of active ingredient according to the
invention surprisingly enables effective treatment, but also prophylaxis of skin ageing
caused by extrinsic and intrinsic factors.

15 The invention particularly relates to the use of a compound of formula (Ia) or (Ib) or a
stereoisomeric form thereof for the preparation of a cosmetic or dermatological
composition.

20 The amount used of the active compound or a stereoisomeric form thereof corresponds to the
amount required to obtain the desired result using the cosmetic or dermatological
compositions. One skilled in this art is capable of evaluating this effective amount, which
depends on the derivative used, the individual on whom it is applied, and the time of this
application. To provide an order of magnitude, in the cosmetic or dermatological
compositions according to the invention, the compound of formula (Ia) or (Ib) or a
stereoisomeric form thereof may be administered in an amount representing from 0.001% to
25 40% by weight, preferentially 0.005% to 30% by weight and more preferentially from
0.01% to 20% by weight.

30 A further aspect covers cosmetic compositions comprising a compound of formula (Ia) or
(Ib) or a stereoisomeric form thereof and at least one cosmetically tolerable component, e.g. a
cosmetically tolerable component for skin applications.

The amounts of the various components of the physiological medium of the cosmetic composition according to the invention are those generally included in the fields under consideration. When the cosmetic composition is an emulsion, the proportion of the fatty phase may range from 2% to 80% by weight and preferably from 5% to 50% by weight relative to the total weight of the cosmetic composition.

Thus, the cosmetic composition should contain a non-toxic physiologically acceptable medium that can be applied to human skin. For a topical application to the skin, the cosmetic composition may be in the form of a solution, a suspension, an emulsion or a dispersion of more or less fluid consistency and especially liquid or semi-liquid consistency, obtained by dispersing a fatty phase in an aqueous phase (O/W) or, conversely, (W/O), or alternatively a gel. A cosmetic composition in the form of a mousse or in the form of a spray or an aerosol then comprising a pressurized propellant may also be provided. Also the compositions may be in the form of a haircare lotion, a shampoo or hair conditioner, a liquid or solid soap, a treating mask, or a foaming cream or gel for cleansing the hair. They may also be in the form of hair dye or hair mascara.

The cosmetic compositions of the invention may also comprise one or more other ingredients usually employed in the fields under consideration, selected from among formulation additives, for instance aqueous-phase or oily-phase thickeners or gelling agents, dyestuffs that are soluble in the medium of the cosmetic composition, solid particles such as mineral or organic fillers or pigments in the form of microparticles or nanoparticles, preservatives, fragrances, hydrotopes or electrolytes, neutralizers (acidifying or basifying agents), propellants, anionic, cationic or amphoteric surfactants, polymers, in particular water-soluble or water-dispersible anionic, nonionic, cationic or amphoteric film-forming polymers, mineral or organic salts, chelating agents; mixtures thereof.

The cosmetic compositions may be used to inhibit the micro-inflammatory cycle. Thus, the present invention also relates to cosmetic compositions comprising a compound of formula (Ia) or (Ib) or a stereoisomeric form thereof that is used for the cosmetic treatment or cosmetic prophylaxis of micro-inflammatory conditions.

Cosmetic compositions comprising a compound of formula (Ia) or (Ib) or a stereoisomeric form thereof that is used for the cosmetic treatment or cosmetic prophylaxis of skin ageing caused by intrinsic factors are also subject of the present invention. Intrinsic factors 5 responsible for skin ageing are genetically programmed determinants including age, hormonal status, and psychological factors.

Beside cosmetically inactive ingredients the cosmetic compositions of the present invention may also comprise one or more cosmetically active ingredients with beneficial 10 action on the skin. Thus, the present invention relates to cosmetic compositions comprising a compound of formula (Ia) or (Ib) or a stereoisomeric form thereof and at least one further cosmetically active ingredient, e.g. an UV-blocker or proteins.

Dermatological compositions comprising a compound of formula (Ia) or (Ib) or a 15 stereoisomeric form thereof and at least one dermatologically tolerable component, e.g. a dermatologically tolerable component for skin applications, are also subject of the invention.

Dermatologically tolerable components that can be used for the dermatological compositions described here are identical to the cosmetically tolerable components as 20 defined in this invention.

A further embodiment of this invention are dermatological compositions comprising a compound of formula (Ia) or (Ib) or a stereoisomeric form thereof that is used for the dermatological treatment, dermatological diagnosis or dermatological prophylaxis of micro-inflammatory conditions. 25

In particular the invention covers dermatological compositions comprising a compound of formula (Ia) or (Ib) or a stereoisomeric form thereof that is used for the dermatological treatment, dermatological diagnosis or dermatological prophylaxis of itching and skin ageing caused by extrinsic factors. Extrinsic factors include environmental factors in general; more

particularly photo-ageing due to exposure to the sun, to light or to any other radiation, atmospheric pollution, wounds, infections, traumatisms, anoxia, cigarette smoke, hormonal status as response to external factors, neuropeptides, electromagnetic fields, gravity, lifestyle (e.g. excessive consumption of alcohol), repetitive facial expressions,
5 sleeping positions, and psychological stressors.

In addition to dermatologically inactive ingredients the dermatological compositions may also comprise dermatologically or pharmaceutically active ingredients. Thus, the present invention also relates to dermatological compositions comprising a compound of formula (Ia) or (Ib) or a stereoisomeric form thereof and at least one further dermatologically or pharmaceutically active ingredient. The dermatologically or pharmaceutically active ingredients that can be used for the dermatological compositions described herein are defined as the cosmetically active ingredients defined above. Dermatologically or pharmaceutically active ingredients can be identical to the cosmetically active ingredients as defined in this invention.
10
15

Another subject of the present invention are dermatological compositions comprising a compound of formula (Ia) or (Ib) or a stereoisomeric form thereof and at least one further dermatologically or pharmaceutically active ingredient characterized in that it is used for the dermatological treatment, dermatological diagnosis or dermatological prophylaxis of micro-inflammatory conditions.

In particular, the present invention relates to dermatological compositions comprising a compound of formula (Ia) or (Ib) or a stereoisomeric form thereof and at least one further dermatologically or pharmaceutically active ingredient characterized in that it is used for the dermatological treatment, dermatological diagnosis or dermatological prophylaxis of itching and skin ageing caused by extrinsic factors.
20

Ageing of the skin may also be caused by a combination of intrinsic and extrinsic factors. Therefore, the present invention also relates to dermatological compositions comprising a compound of formula (Ia) or (Ib) or a stereoisomeric form thereof and at least one further pharmaceutically or cosmetically active ingredient characterized in that it is used for the
25

- 30 -

cosmetic and dermatological treatment and cosmetic and dermatological prophylaxis of skin ageing caused by a combination of intrinsic and extrinsic factors.


Another embodiment of this invention is a process for the preparation of a cosmetic composition by mixing a compound of formula (Ia) or (Ib) or a stereoisomeric form thereof, at 5 least one cosmetically tolerable component and eventually further cosmetically active ingredients.

In particular, a process for the preparation of a cosmetic composition by mixing a compound of formula (Ia) or (Ib) or a stereoisomeric form thereof, at least one cosmetically tolerable component and eventually further cosmetically active ingredients, wherein the composition 10 includes from 0.01% to 20% by weight of compound of formula (Ia) or (Ib) or a stereoisomeric form thereof, based on the total weight of the composition is subject of this invention.

A further aspect deals with a process for the preparation of a dermatological composition by mixing a compound of formula (Ia) or (Ib) or a stereoisomeric form thereof, at least one 15 dermatologically tolerable component and eventually further pharmaceutically active ingredients.


Many of the compounds of the present invention may be synthesized according to the following general synthetic schemes.

- 31 -

SCHEME 1

In SCHEME 1 an amino acid of type (1) is reacted to the corresponding methyl ester (2) under heating with acidic methanol. Ester (2) is reacted with a trimethoxy-phenyl-alkylic acid under state-of-the-art conditions (i.e. N'-(3-dimethylaminopropyl)-N-ethyl carbodiimide (EDC), triethylamine and 4-dimethylaminopyridine (DMAP) in a chlorinated solvent) to the amide (3). Alternatively diisopropyl carbodiimide (DIC) and hydroxybenzotriazole (HOBr) may be used for this reaction step. The synthesis sequence shown in SCHEME 1 leading to compounds like (3) is not only reduced to the Y-H building blocks like (1) but may be generally applied to all other Y-H type building blocks leading to compounds of type (A1), (A2), (B1) and (B2) as shown in the paragraph before.


SCHEME 2




In SCHEME 2 a carboxy substituted thiophene like (4) is reacted to the corresponding ethyl ester (5) under heating in acidic ethanol. Ester (5) is brominated with N-bromosuccinimide in anhydrous chloroform and glacial acetic acid to give (6) which is further reacted with 2-Amino-benzeneboronic acid under a state-of-the-art Suzuki transformation (i.e. Tetrakis(triphenylphosphine)-palladium, aqueous sodium carbonate, ethanol, toluene) to the biaryl (7). Biaryl (7) is reacted with a trimethoxy-phenyl-alkylic acid, EDC, triethylamine and DMAP in a chlorinated solvent to the amide (8).

10 Alternatively DIC and HOBr may be used for this reaction step.

- 33 -

SCHEME 3

In SCHEME 3 Methyl-3-bromobenzoate (9) is reacted under inert conditions with a Trimethoxyphenylboronic acid under Suzuki-type basic conditions ($Pd(PPh_3)_4$ and aqueous sodium bicarbonate in dimethoxyethane) to a biphenyl of type (10) which is further hydrolyzed with aqueous lithium hydroxide in acetonitrile to give the corresponding carboxylic acid (11) which was converted to building block of type (12) by reaction with oxalyl chloride in anhydrous dichloromethane.


SCHEME 4

In SCHEME 4 an acid chloride like (12) is reacted with an aniline of general type (13) under basic conditions (triethylamine in a chlorinated solvent) to form the anilide (14). Alternatively pyridine may be used for this reaction step.

In case that R² and/or R⁴ contain carboxylic acid functionalities, those are protected as their corresponding methyl or ethyl esters before and hydrolized afterwards to release the carboxylic acid functionalities. The ester hydrolysis is done with LiOH in MeCN or THF/MeOH.


- 5 The synthesis sequence shown in SCHEME 4 leading to compounds like (14) is not only reduced to X-Y-H and Y-H building blocks like (13) but may be generally applied to all other X-Y-H and Y-H type building blocks leading to compounds of type (A1), (A2), (B1) and (B2) as shown in the paragraphs before.

10

SCHEME 5

- In SCHEME 5 the generation of building block (19) is outlined, whereby the furane (16) is available by NBS-bromination of methyl furoate (15) and pinacolyl borane of type (18) is available by Pd-catalyzed boration of anilines like (17). Suzuki-type coupling of (16) and (18) with Pd(PPh₃)₄ leads to biaryls of type (19).
- 15

- 35 -

SCHEME 6

In SCHEME 6 a biaryl of type (19) is reacted with a trimethoxy-phenyl-alkylic acid under state-of-the-art conditions (i.e. N’-(3-dimethylaminopropyl)-N-ethyl carbodiimide (EDC), triethylamine and 4-dimethylaminopyridine (DMAP) in a chlorinated solvent) to the amide of type (20). Alternatively diisopropyl carbodiimide (DIC) and hydroxybenzotriazole (HOBr) may be used for this reaction step. (20) is then hydrolyzed to acid of type (21) whether with LiOH in MeCN or THF/MeOH.

The present invention is furthermore illustrated by the following representative examples.

15


20

EXAMPLE 1

{3-[3-(2,3,4-Trimethoxy-phenyl)-propionylamino]-phenyl}-acetic acid methyl ester
(24)

5

SCHEME 7



Step 1: Dissolve (3-Amino-phenyl)-acetic acid ((22), 700mg, 4.63mmol) in MeOH (21mL) and add conc. sulfuric acid (0.27mL, 5.09mmol). Stir the reaction mixture for 2d under reflux. Cooled mixture to room temperature (rt), remove solvent under reduced pressure and prepurify the residue by flushing it over a short pad of silica gel using EtOAc. Remove solvent again and partition the residue between EtOAc and saturated aqu. NaHCO₃ (1+1). Extracte the aqueous layer 3 times with EtOAc, washe the combined organic layers with brine and dried with Na₂SO₄. Remove solvent under reduced pressure and dry the residue without further purification in oil pump vacuum to obtain product (23) as a light yellow oil (708mg, 92%). ¹H NMR (400MHz, CDCl₃): 3.51 (s, 2 H); 3.67 (s, 3 H); 6.57 (dd, 1 H, *J*₁ = 7.8Hz, *J*₂ = 1.8Hz); 6.60 (br.ηt, 1 H, *J* = 1.8Hz); 6.65 (br.d, 1 H, *J* ≈ 7.8Hz); 7.08 (ηt, 1 H, *J* = 7.8Hz).

Step 2: (The following reaction is done in an anhydrous N₂ atmosphere.) Dissolve EDC hydrochloride (187mg, 0.98mmol) and triethylamine (0.14mL, 1.00mmol) in anhydrous dichloromethane (3.5mL) and stir for 5min at rt. Added 3-(2,3,4-Trimethoxy-

- 37 -

phenyl)-propionic acid (234mg, 0.97mmol) and DMAP (12mg, 0.10mmol) and stir for 10min. Add ester (23) (107mg, 0.65mmol) and stir the reaction solution overnight at rt.

Hydrolize the reaction solution with saturated aqu. NH₄Cl followed by water, separate layers, extracte aqu. layer with dichloromethane (3 times) and washe the combined organic 5 layers with water and brine and dry with Na₂SO₄. Remove solvent under reduced pressure.

Purify crude product by preparative radial chromatography (silica gel 60PF, EtOAc/CyH 1+1) to obtain product (24) as a white solid (209mg, 83%). [K. C. Nicolaou; P. S. Baran; Y.-L. Zhong; K. Sugita; *J. Am. Chem. Soc.*; **2002**; *124*; 10; 2212-2220]. ¹H NMR (400MHz, CDCl₃): 2.62 (t, 2 H, *J* = 7.5Hz); 2.95 (t, 2 H, *J* = 7.5Hz); 3.58 (s, 2 H); 3.67 (s, 10 3 H); 3.82 (s, 3 H); 3.84 (s, 3 H); 3.91 (s, 3 H); 6.59 (d, 1 H, *J* = 8.6Hz); 6.86 (d, 1 H, *J* = 8.6Hz); 6.98 (br.d, 1 H, *J* = 7.8Hz); 7.32 (Ψ t, 1 H, *J* = 7.8Hz); 7.38 (br.d, 1 H, *J* = 7.8Hz); 7.41 (br.s, 1 H).

15

20


25

- 38 -

EXAMPLE 2

(5-{2-[2-(2,3,4-Trimethoxyphenyl)-acetylamino]-phenyl}-thiophen-2-yl)acetic acid (31)

5

SCHEME 8

Step 1: Dissolve Thiophene-2-yl-acetic acid (25) (2.44g, 17.1mmol) in ethanol (35mL) and add fuming aqu. hydrochloric acid (few drops). Stir the reaction mixture for 19h at 70 °C. Cool mixture to rt, remove solvent under reduced pressure and resolve the residue in EtOAc. Wash this organic layer 3 times with 5% aqu. Na₂CO₃ and extract the combined aqueous layer 3 times with EtOAc. Wash the combined organic layers with brine and dry with Na₂SO₄. Remove solvent under reduced pressure and dry the residue without further purification in oil pump vacuum to obtain product (26) as a light brown oil (2.78g, 95%). [J. Kunes; V. Balsanek; M. Pour; V. Buchta; *Collect. Czech. Chem. Commun.*, **2001**, 66; 12; 1809-1830]. ¹H NMR (400MHz, CDCl₃): 1.26 (t, 3 H, J = 7.1 Hz); 3.81 (s, 2 H); 4.17 (q, 2 H, J = 7.1 Hz); 6.91-6.96 (m, 2 H); 7.20 (d, 1H, J = 4.8 Hz).

Step 2: (The following reaction is done in an anhydrous N₂ atmosphere.) Dissolve ester (26) (1.30g, 7.64mmol) in anhydrous chloroform (6.0mL) and glacial acetic acid (6.0mL), add N-Bromosuccinimide (1.39g, 7.79mmol) in portions and stir the mixture for 23h at rt. The mixture is diluted with an equal volume of water, the organic layer separated and washed with a 1M aqu. NaOH, water, again with 1M aqu. NaOH and water (2 times). Finally wash the organic layer with brine and dry with Na₂SO₄. Remove solvent under reduced pressure. Purify crude product by preparative radial chromatography (silica gel 60PF, CyH/EtOAc 5+1] to obtain product (27) as an impure (according to NMR: 20% sideproduct) orange liquid (1.61g, 85%) which is used without any further purification. [P. M. Jackson; C.J. Moody; P. Sha; *J. Chem. Soc. Perkin Trans. 1*; **1990**; 2909-2918]. ¹H NMR (400MHz, CDCl₃): 1.26 (t, 3 H, J = 7.1 Hz), 3.73 (s, 2 H); 4.17 (q, 2 H, J = 7.1 Hz); 6.67 (d, 1 H, J = 3.5 Hz); 6.88 (d, 1 H, J = 3.5 Hz).

Step 3: (The following reaction is done in an oxygenfree N₂ atmosphere.) Ethanol (1.47mL), Tetrakis-(triphenylphosphine)-palladium(0) (59.0mg, 2.5mol%) and aqu. Na₂CO₃ (1.60g, 5.60mmol; presolved in 2.0mL H₂O) are subsequently added to dissolved 2-Amino-benzeneboronic acid (28) (341mg, 2.20 mmol) in toluene (16mL). The reaction mixture is degassed 5 times and flooded with N₂ again. Add bromide (27) (498mg, 2.00mmol) and rinse with toluene (4.5 mL), degas again (5 times) and stir the reaction solution 21h at 100°C. Partition the reaction solution between EtOAc and brine (1+1) and extract the separated aqueous layer 3 times with EtOAc. Wash combined organic layer with brine and dry with Na₂SO₄. Remove solvent under reduced pressure and purify the

- 40 -

crude product by preparative radial chromatography (silica gel 60PF, CyH/EtOAc 6+1, later 3+1) to obtain product (29) as a light yellow solid (300mg, 57%). [N. Miyaura; A. Suzuki; *Chem. Rev.*; **1995**; *95*; 2457]. ^1H NMR (400MHz, CDCl_3): 1.28 (t, 3 H, J = 7.1 Hz); 3.82 (s, 2 H); 4.19 (q, 2 H, J = 7.1 Hz); 6.77-6.84 (m, 2 H); 6.91 (d, 1 H, J = 3.5 Hz); 7.04 (d, 1 H, J = 3.5 Hz); 7.13 (td, 1 H, J = 7.8 Hz, 1.3 Hz); 7.25 (d, 1 H, J = 7.8 Hz).


Step 4: (The following reaction is done in an anhydrous N_2 atmosphere.) Suspend EDC hydrochloride (86.3mg, 0.45mmol) in anhydrous dichloromethane (1.4mL), add triethylamine (0.063mL, 0.45mmol) and stir for 10min at rt. Add 2-(2,3,4-Trimethoxy-phenyl)-acetic acid (74.7mg, 0.33mmol) and DMAP (3.7mg, 0.03mmol) and stir for 15min. Added ester (29) (64.9mg, 0.30mmol) and stir the reaction solution 22h at rt. Partition the reaction solution between dichloromethane and water (1+1), separate layers and extract aqu. layer with dichloromethane (3 times). Wash the combined organic layer with brine and dry with Na_2SO_4 . Purify crude product by preparative radial chromatography (silica gel 60PF, CyH/EtOAc 3+2) to obtain product (30) as yellow oil (118mg, 84%). ^1H NMR (400MHz, CDCl_3): 1.29 (t, 3 H, J = 7.1 Hz); 3.58 (s, 2 H); 3.74 (s, 3 H); 3.78 (s, 3 H); 3.79-3.80 (m, 2 H); 3.86 (s, 2 H); 4.20 (q, 2 H, J = 7.1 Hz); 6.58 (d, 1 H, J = 8.6 Hz); 6.59 (d, 1 H, J = 3.5 Hz); 6.75 (d, 1 H, J = 3.5 Hz); 6.85 (d, 1 H, J = 8.6 Hz); 7.05 (t, 1 H, J =7.8 Hz); 7.26 (dd, 1 H, J = 7.8 Hz, 1.3 Hz); 7.30 (td, 1 H, J = 7.8 Hz, 1.3 Hz); 7.90 (br.s; 1 H), 8.38 (d, 1 H, J = 8.3 Hz).

Step 5: Dissolve ester (30) (118mg, 0.25mmol) in methanol (8.0mL), add a 1M aqu. LiOH solution (1.76mL, 1.76mmol) and stir 20h at rt. Remove solvent under reduced pressure und partition residue between CHCl_3 and 0.5M HCl (1+1). Separate the aqueous layer and extract 3 times with CHCl_3 . Wash the combined organic layer with brine and dry with Na_2SO_4 . Remove solvent under reduced pressure and dry the residue without further purification in oil pump vacuum to obtain crude product (31) as light brown foam (120mg, quant.). ^1H NMR (400MHz, CDCl_3): 3.58 (s, 2 H); 3.73 (s, 3 H); 3.78 (s, 3 H); 3.85 (s, 2 H); 3.86 (s, 3 H); 6.58-6.61 (m, 1 H); 6.59 (d, 1 H, J = 8.3 Hz); 6.77 (d, 1 H, J = 3.5 Hz); 6.86 (d, 1 H, J = 8.3 Hz); 7.06 (t, 1 H, J = 7.8 Hz); 7.22-7.27 (m, 1 H); 7.31 (td, 1 H, J = 7.8 Hz, 1.3 Hz); 7.86 (br.s, 1 H); 8.37 (d, 1 H, J = 8.3 Hz).

EXAMPLE 3

5 **(5-{2-[(2',3',4'-Trimethoxy-biphenyl-3-carbonyl)-amino]-phenyl}-thiophen-2-yl)-acetic acid methyl ester (37)**

SCHEME 9



10

Step 1: (The following reaction is done in an N₂ atmosphere.) To a solution of 2,3,4-Trimethoxyphenylboronic acid (32) (1.40g, 6.60mmol) in toluene (15.0mL) is added EtOH (2.0mL), Pd(PPh₃)₄ (208mg, 0.18mmol) and Na₂CO₃·10H₂O (4.81g, 16.80mmol) in water (5.2mL). The resulting mixture is carefully degassed (5 times alternating vacuum 15 and flushing with N₂). A solution of Methyl-3-bromobenzoate (9) (1.29g, 6.00mmol) in

toluene (9.0mL) is added by syringe, the resulting mixture is again carefully degassed and stirred overnight at 100°C. Partition the mixture between brine/EtOAc (1+1), separate layers, extract the aqu. layer with EtOAc (3x), wash the combined organic layer with brine, dry with Na₂SO₄ and remove solvent. Purify crude product by preparative radial chromatography (silica gel, EtOAc/CyH 1+5) to obtain 2',3',4'-Trimethoxy-biphenyl-3-carboxylic acid methyl ester (33) as a yellowish oil (1.07g, 58%). ¹H NMR (400MHz, CDCl₃): 3.66 (s, 3 H); 3.89 (s, 3 H); 3.92 (s, 6 H); 6.74 (d, 1 H, *J* = 8.6Hz); 7.03 (d, 1 H, *J* = 8.6Hz); 7.44 (t, 1 H, *J* = 7.8Hz); 7.70 (d, 1 H, *J* = 7.6Hz); 7.97 (d, 1 H, *J* = 7.8Hz); 8.15 (br.s 1 H).

Step 2: Dissolve 2',3',4'-Trimethoxy-biphenyl-3-carboxylic acid methyl ester (33) (566mg, 1.87mmol) in MeCN (19.0mL) at rt and add 1M aqu LiOH (9.36mL, 9.36mmol). Stir reaction mixture overnight at rt. Quench reaction mixture (cooling bath) with 1M aqu. HCl (to get pH ca. 3). Extract the mixture with EtOAc (3x), wash the combined organic layer with brine and dry with Na₂SO₄. Recrystallize crude product from EtOAc/CyH 1+3 to obtain 2',3',4'-Trimethoxy-biphenyl-3-carboxylic acid (34) as a white solid (392mg, 72%). ¹H NMR (400MHz, CD₃OD: 3.68 (s, 3 H); 3.93 (br.s, 6 H); 6.92 (d, 1 H, *J* = 8.6Hz); 7.11 (d, 1 H, *J* = 8.6Hz); 7.54 (t, 1 H, *J* = 7.7Hz); 7.75 (d, 1 H, *J* = 7.6Hz); 8.01 (d, 1 H, *J* = 7.8Hz); 8.18 (br.s 1 H).

Step 3: (The following reaction is done in an anhydrous N₂ atmosphere.) Dissolve 2',3',4'-Trimethoxy-biphenyl-3-carboxylic acid (34) (107mg, 0.37mmol) in anhydrous DCM (3.0mL) and add anhydrous DMF (3 drops, cat. amount). Then add slowly oxalyl chloride (42μL, 0.48mmol) by keeping temperature at ca. 15°C with a water bath and stir the turbid mixture for additional 2h at rt. Transfer the formed crude solution of 2',3',4'-Trimethoxy-biphenyl-3-carbonyl chloride (35) to an ice cooled solution of [5-(2-Amino-phenyl)-thiophen-2-yl]-acetic acid methyl ester (36) (70mg, 0.28mmol) in anhydrous DCM (4.5mL) and anhydrous pyridine (0.75mL). Stir the reaction mixture for 3h at rt. Pour the reaction mixture into ice cooled 1M aqu. HCl, extract with DCM (3x), wash the combined organic layer with brine and dry with Na₂SO₄. Purify the crude product by preparative radial chromatography (silica gel, EtOAc/CyH 1+3, later 1+2) to obtain (5-{2-[2',3',4'-Trimethoxy-biphenyl-3-carbonyl]-amino}-phenyl)-thiophen-2-yl)-acetic acid methyl ester (37) as a brownish sticky solid (96mg, 65%). ¹H NMR (400MHz, CDCl₃): 3.64 (s, 3 H);

- 43 -

3.71 (s, 3 H); 3.84 (s, 2 H); 3.90 (s, 3 H); 3.92 (s, 3 H); 6.75 (d, 1 H, *J* = 8.8Hz); 6.97 (d, 1 H, *J* = 3.5Hz); 7.01 (d, 1 H, *J* = 8.8Hz); 7.03 (d, 1 H, *J* = 3.5Hz); 7.16 (br.t, 1 H, *J* = 7.6Hz); 7.36-7.43 (m, 2 H); 7.46 (t, 1 H, *J* = 7.7Hz); 7.67 (Ψ dd, 2 H, *J₁* = 7.6Hz, *J₂* = 1.5Hz); 7.91 (br.s 1 H); 8.41 (br.s 1 H); 8.50 (d, 1 H, *J* = 8.6Hz).


5

EXAMPLE 4

5-{2-Amino-4-[2-(3,4,5-trimethoxy-phenyl)-acetylamino]-phenyl}-2-methyl-furan-3-carboxylic acid (42)

10

SCHEME 10



Step 1: (The following reaction is done under exclusion of light.) Dissolve 2-Methyl-furan-3-carboxylic acid methyl ester (15) (2.00mL, 15.9mmol) in chloroform (11mL) and glacial acetic acid (11mL) and add NBS (3.85g, 21.6mmol) portionwise in between a period of 75min. Stir the reaction suspension for additional 16h at rt. Add water to the reaction mixture and extract the aqu. layer with DCM (2 times), wash the combined organic layer with 2M aqu. NaOH, water and brine and dry it with Na_2SO_4 to obtain 5-Bromo-2-methyl-furan-3-carboxylic acid methyl ester (16) (2.80g, 80%) as a red brown oil. No further purification. ^1H NMR (400MHz, CDCl_3): 2.54 (s, 3 H); 3.80 (s, 3 H); 6.53 (s, 1 H).

Step 2: (The following reaction is done in a N_2 atmosphere.) Dissolve $\text{PdCl}_2(\text{dpdpf})\text{CH}_2\text{Cl}_2$ (245mg, 0.30mmol), KOAc (2.52g, 25.7mmol) and Bis-(pinacolato)diboron (3.81g, 15.00mmol) in anhydrous DMSO (50mL) and add 4-Bromo-3-nitro-phenylamine (38) (2.17g, 10.00mmol). Degas the mixture carefully and flush with N_2 again (5 times) and stir it for 24h at 80°C. Cool the reaction mixture to rt and partition it between water and toluene. Extract the aqu. layer with EtOAc (3 times), wash the combined organic layer with water and brine and dry it with Na_2SO_4 . The obtained crude residue is filtrated through a short pad of silica gel using EtOAc/CyH (1+1) to obtain 3-Nitro-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenylamine (39) (2.04g, 77%) as a dark red solid. No further purification. ^1H NMR (400MHz, CDCl_3): 1.37 (s, 12 H); 3.95 (br.s, 2 H); 6.87 (dd, 1 H, $J_1 = 7.8\text{Hz}$, $J_2 = 2.3\text{Hz}$); 7.30 (d, 1 H, $J = 8.1\text{Hz}$); 7.35 (d, 1 H, $J = 2.3\text{Hz}$).

Step 3: (The following reaction is done in a N_2 atmosphere.) Dissolve $\text{Pd}(\text{PPh}_3)_4$ (59mg, 0.05mmol) and 5-Bromo-2-methyl-furan-3-carboxylic acid methyl ester (23) (447mg, 2.04mmol) in DME (3mL) and stir for 10min at rt. Add 3-Nitro-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenylamine (39) (465mg, 1.76mmol) followed by an aqu. 1M sodium bicarbonate solution (5.10mL, 5.10mmol). Degas the reaction mixture carefully, flush with N_2 (5 times) and stir for 4,5h at 90°C (reflux). Cool reaction mixture to rt, remove organic solvent under reduced pressure and partition the residue between water and EtOAc. Extract the aqu. layer with EtOAc (3 times), wash the combined organic layer with water and brine and dry it with Na_2SO_4 . Purify the obtained crude product by flash chromatography (silica gel, EtOAc/CyH 1+3, later 1+2) to obtain 5-(4-Amino-2-

- 45 -

nitro-phenyl)-2-methyl-furan-3-carboxylic acid methyl ester (40) (167mg, 34%) as a red solid. ^1H NMR (400MHz, CDCl_3): 2.57 (s, 3 H); 3.81 (s, 3 H); 4.05 (br.s, 2 H); 6.68 (s, 1 H); 6.81 (dd, 1 H, $J_1 = 8.3\text{Hz}$, $J_2 = 2.3\text{Hz}$); 6.99 (d, 1 H, $J = 2.3\text{Hz}$); 7.39 (d, 1 H, $J = 8.3\text{Hz}$).

5 **Step 4:** (The following reaction is done in an anhydrous N_2 atmosphere.) Suspend EDC·HCl (138mg, 0.72mmol) and Et_3N (101 μL , 0.72) in anhydrous DCM (4.5mL) and stir the resulting solution for 5min at rt. Add 2-(3,4,5-Trimethoxy-phenyl)-acetic acid (163mg, 0.72mmol) and DMAP (8mg, 0.07mmol) and stir the resulting solution for 10min. Add 5-(4-Amino-2-nitro-phenyl)-2-methyl-furan-3-carboxylic acid methyl ester (40) (100mg, 10 0.36mmol) and stir the reaction solution for 22h at rt. Quench reaction solution with sat. aqu. NH_4Cl and water, separate layers and extract aqu. layer with DCM (3 times). Wash the combined organic layer with water and brine and dry with Na_2SO_4 . Purify the crude product by preparative radial chromatography (silica gel, EtOAc/CyH 1+1) to obtain 2-Methyl-5-{2-nitro-4-[2-(3,4,5-trimethoxy-phenyl)-acetylamino]-phenyl}-furan-3-carboxylic acid methyl ester (41) (96mg, 55%) as an yellow solid. ^1H NMR (400MHz, CDCl_3): 2.55 (s, 3 H); 3.65 (s, 2 H); 3.79 (s, 3 H); 3.81 (s, 6 H); 3.82 (s, 3 H); 6.50 (s, 2 H); 6.77 (s, 1 H); 7.53 (d, 1 H, $J = 8.6\text{Hz}$); 7.66 (dd, 1 H, $J_1 = 8.6\text{Hz}$, $J_2 = 2.0\text{Hz}$); 7.93 (br.s, 1 H); 7.96 (d, 1 H, $J = 2.0\text{Hz}$).


20 **Step 5:** Dissolve 2-Methyl-5-{2-nitro-4-[2-(3,4,5-trimethoxy-phenyl)-acetylamino]-phenyl}-furan-3-carboxylic acid methyl ester (41) (50mg, 0.10mmol) in THF (1.0mL) and MeOH (0.5mL) at rt and add 1M aqu LiOH (525 μL , 0.52mmol). Stir the reaction mixture for 17h at rt. Add dropwise 1M aqu. HCl (580 μL , 0.58mmol) and extract the mixture with EtOAc (3 times), wash the combined organic layer with brine and dry it with Na_2SO_4 . Purify the obtained crude product by preparative TLC (silica gel, 25 EtOAc/MeOH 9+1) to obtain 2-Methyl-5-{2-nitro-4-[2-(3,4,5-trimethoxy-phenyl)-acetylamino]-phenyl}-furan-3-carboxylic acid (42) (35mg, 71%) as a brown sticky solid. ^1H NMR (400MHz, CDCl_3): 2.61 (s, 3 H); 3.70 (s, 2 H); 3.86 (s, 3 H); 3.87 (s, 6 H); 6.51 (s, 2 H); 6.85 (s, 1 H); 7.29 (br.s, 1 H); 7.58 (d, 1 H, $J = 8.6\text{Hz}$); 7.62 (dd, 1 H, $J_1 = 9.0\text{Hz}$, $J_2 = 2.2\text{Hz}$); 7.98 (d, 1 H, $J = 2.0\text{Hz}$).

EXAMPLE 5

{4-[2-(3,4,5-Trimethoxy-phenyl)-acetyl]-piperazin-1-yl}-acetic acid ethyl ester (**44**)

5

SCHEME 11




(The following reaction is done in an anhydrous N₂ atmosphere.) Suspend EDC·HCl (188mg, 0.98mmol) and Et₃N (137μL, 0.98mmol) in anhydrous DCM (1.0mL) and stir the resulting solution for 5min at rt. Add 2-(3,4,5-Trimethoxy-phenyl)-acetic acid (163mg, 0.72mmol) and DMAP (8mg, 0.07mmol) and stir the resulting solution for 10min. Add 1-(Ethoxycarbonylmethyl)piperazine (**43**) (112mg, 0.65mmol) and stir the reaction solution overnight at rt. Quench reaction solution with sat. aqu. NH₄Cl and water, separate layers and extract aqu. layer with DCM (3 times). Wash the combined organic layer with water and brine and dry with Na₂SO₄. Purify the crude product by preparative radial chromatography (silica gel, EtOAc/MeOH 10+1) to obtain {4-[2-(3,4,5-Trimethoxy-phenyl)-acetyl]-piperazin-1-yl}-acetic acid ethyl ester (**44**) (99mg, 40%) as a colorless oil.
¹H NMR (400MHz, CDCl₃): 1.25 (t, 3 H, J = 7.1Hz); 2.48 (br.m, 2 H); 2.58 (br.m, 2 H); 3.21 (br.s, 2 H); 3.53 (br.m, 2 H); 3.65 (s, 2 H); 3.71 (br.m, 2 H); 3.81 (s, 3 H); 3.82 (s, 6 H); 4.16 (q, 2 H, J = 7.1Hz); 6.42 (s, 2 H).

EXAMPLE 6

{4-[3-(3,4,5-Trimethoxy-phenyl)-propionyl]-piperazin-1-yl}-acetic acid (46)

SCHEME 12



Step 1: (The following reaction is done in an anhydrous N₂ atmosphere.) Suspend EDC·HCl (376mg, 1.96mmol) and Et₃N (275μL, 1.96mmol) in anhydrous DCM (2.0mL) and stir the resulting solution for 5min at rt. Add 3-(3,4,5-Trimethoxy-phenyl)-propionic acid (346mg, 1.44mmol) and DMAP (17mg, 0.14mmol) and stir the resulting solution for 15min. Add 1-(Ethoxycarbonylmethyl)piperazine (43) (224mg, 1.30mmol) and stir the reaction solution overnight at rt. Quench reaction solution with water, separate layers and extract aqu. layer with EtOAc (3 times). Filtrate the combined organic layer through a short pad of silica gel and remove solvent. Purify the crude product by preparative radial chromatography (silica gel, EtOAc/MeOH 9+1) to obtain {4-[3-(3,4,5-Trimethoxy-phenyl)-propionyl]-piperazin-1-yl}-acetic acid ethyl ester (45) (426mg, 83%) as a colorless oil. ¹H NMR (400MHz, CDCl₃): 1.26 (t, 3 H, J = 7.1Hz); 2.45-2.70 (br.m, 6 H); 2.89 (t, 2 H, J = 7.7Hz); 3.26 (br.s, 2 H); 3.43-3.56 (br.m, 2 H); 3.61-3.76 (br.m, 2 H); 3.80 (s, 3 H); 3.83 (s, 6 H); 4.18 (q, 2 H, J = 7.1Hz); 6.41 (s, 2 H).

- 48 -

Step 2: Dissolve {4-[3-(3,4,5-Trimethoxy-phenyl)-propionyl]-piperazin-1-yl}-acetic acid ethyl ester (45) (100mg, 0.25mmol) in MeOH (2.0mL) at rt and add 2M aqu NaOH (260 μ L, 0.52mmol). Stir the reaction mixture for 1h under reflux. Add dropwise 1M aqu. HCl (550 μ L, 0.55mmol), extract the mixture with EtOAc (3 times) and remove solvent obtain {4-[3-(3,4,5-Trimethoxy-phenyl)-propionyl]-piperazin-1-yl}-acetic acid (46) (88mg, 95%) as a brown sticky solid. No further purification. 1 H NMR (400MHz, CDCl₃/CD₃OD 9+1): 2.54 (br.t, 2 H); 2.78 (t, 2 H, *J* = 7.5Hz); 2.83-3.10 (br.m, 2 H); 3.24 (s, 2 H); 3.43-3.62 (br.m, 2 H); 3.68 (s, 3 H); 3.73 (s, 6 H); 3.74-3.85 (br.m, 4 H); 6.34 (s, 2 H).


10

EXAMPLE 7

{2'-[3-(3,4,5-Trimethoxy-phenyl)-propionylamino]-biphenyl-3-yl}-acetic acid methyl ester (50)

15

SCHEME 13



Step1: (The following reaction is done in an oxygenfree N₂ atmosphere.) Add ethanol (0.8mL), Tetrakis-(triphenylphosphine)-palladium(0) (30mg, 2.2mol%) and 20 Na₂CO₃ decahydrate (944mg, 3.30mmol; presolved in 1.2mL H₂O) subsequently to

- 49 -


dissolved 2-Amino-benzeneboronic acid (48) (201mg, 1.30 mmol) in toluene (6.0mL). Degas the reaction mixture for 5 times and flood with N₂ again. Add (3-Bromo-phenyl)-acetic acid methyl ester (47) (270mg, 1.18mmol) in toluene (6.0 mL), degas again (5 times) and stir the reaction solution overnight at 100°C. Partition the reaction solution
5 between EtOAc and brine (1+1) and extract the separated aqueous layer 3 times with EtOAc. Wash combined organic layer with brine and dry with Na₂SO₄. Remove solvent under reduced pressure and purify the crude product by preparative radial chromatography (silica gel 60PF, CyH/EtOAc 3+1) to obtain (2'-Amino-biphenyl-3-yl)-acetic acid methyl ester (49) as an orange oil (304mg, 81%). ¹H NMR (400MHz, CDCl₃): 3.66 (s, 2 H); 3.69
10 (s, 3 H); 3.62-3.86 (br.s, 2 H); 6.75 (d, 1 H, J = 8.1Hz); 6.80 (t, 1 H, J = 7.3Hz); 7.11 (d, 1 H, J = 7.3Hz); 7.15 (d, 1 H, J = 8.1Hz); 7.22-7.26 (br.m, 1 H); 7.32-7.42 (m, 3 H).

Step 2: (The following reaction is done in an anhydrous N₂ atmosphere.) Suspend EDC·HCl (61mg, 0.32mmol) and Et₃N (44μL, 0.32mmol) in anhydrous DCM (1.0mL) and stir the resulting solution for 5min at rt. Add 3-(3,4,5-Trimethoxy-phenyl)-propionic acid
15 (55mg, 0.23mmol) and DMAP (2mg, 0.02mmol) and stir the resulting solution for 15min. Add (2'-Amino-biphenyl-3-yl)-acetic acid methyl ester (49) (50mg, 0.21mmol) and stir the reaction solution overnight at rt. Quench reaction solution with water, separate layers and extract aqu. layer with DCM (3 times). Wash combined organic layer with brine and dry with Na₂SO₄. Purify the crude product by preparative radial chromatography (silica gel,
20 EtOAc/CyH 1+1) to obtain {2'-[3-(3,4,5-Trimethoxy-phenyl)-propionylamino]-biphenyl-3-yl}-acetic acid methyl ester (50) (46mg, 48%) as a yellow oil. ¹H NMR (400MHz, CDCl₃): 2.50 (t, 2 H, J = 7.6Hz); 2.90 (t, 2 H, J = 7.7Hz); 3.64 (s, 2 H); 3.65 (s, 3 H); 3.77 (s, 6 H); 3.78 (s, 3 H); 6.38 (s, 2 H); 7.09-7.18 (m, 3 H); 7.19-7.28 (m, 3 H); 7.34 (d, 1 H, J = 8.1Hz); 7.38 (d, 1 H, J = 7.8Hz); 8.31 (br.d, 1 H, J = 7.8Hz).

EXAMPLE 8

4-[3-(3,4,5-Trimethoxy-phenyl)-propionylamino]-benzoic acid methyl ester (52)

5


SCHEME 14

(The following reaction is done in an anhydrous N_2 atmosphere.) Suspend EDC·HCl (80mg, 0.41mmol) and Et_3N (58 μL , 0.41mmol) in anhydrous DCM (2.0mL) and stir the resulting solution for 5min at rt. Add 3-(3,4,5-Trimethoxy-phenyl)-propionic acid (70mg, 0.29mmol) and DMAP (5mg, 0.04mmol) and stir the resulting solution for 10min. Add 4-Amino-benzoic acid methyl ester (51) (42mg, 0.27mmol) and stir the reaction solution 2d at rt. Quench reaction solution with water, separate layers and extract aqu. layer with DCM (3 times). Wash combined organic layer with brine, dry with Na_2SO_4 and filtrate it through a short pad of silica gel using EtOAc to obtain 4-[3-(3,4,5-Trimethoxy-phenyl)-propionylamino]-benzoic acid methyl ester (52) (91mg, 88%) as a white solid. No further purification. ^1H NMR (400MHz, CDCl_3): 2.60 (t, 2 H, $J = 7.6\text{Hz}$); 2.91 (t, 2 H, $J = 7.6\text{Hz}$); 3.70 (s, 6 H); 3.76 (s, 3 H); 3.83 (s, 3 H); 6.35 (s, 2 H); 7.55 (d, 2 H, $J = 8.3\text{Hz}$); 7.91 (d, 2 H, $J = 8.6\text{Hz}$); 8.09 (s, 1 H).

20

EXAMPLE 9

5 **(5-{2-[{(3',4',5'-Trimethoxy-biphenyl-2-carbonyl)-amino]-phenyl}-thiophen-2-yl)-acetic acid (59)}**

SCHEME 15

Step 1: (The following reaction is done in an N₂ atmosphere.) To a solution of Methyl-2-bromobenzoate (53) (922mg, 4.29mmol) in toluene (11mL) is added Pd(PPh₃)₄ (297mg, 0.26mmol) and Na₂CO₃·10H₂O (3.43g, 12.00mmol) in water (3.8mL). Degas the resulting mixture is carefully (5 times alternating vacuum and flushing with N₂). Add a 5 solution of 3,4,5-Trimethoxyphenylboronic acid (54) (1.00g, 4.72mmol) in toluene (10mL) by syringe, degas the resulting mixture again carefully and stir the resulting mixture overnight at 100°C. Partition the mixture between brine/EtOAc (1+1), separate layers, extract the aqu. layer with EtOAc (3x), wash the combined organic layer with brine and dry with Na₂SO₄. Purify the crude product by flash chromatography (silica gel, 10 EtOAc/CyH 1+7, later 1+5) to obtain 3',4',5'-Trimethoxy-biphenyl-2-carboxylic acid methyl ester (55) as a yellow solid (1.30g, 99%). ¹H NMR (400MHz, CDCl₃): 3.65 (s, 3 H); 3.84 (s, 6 H); 3.87 (s, 3 H); 6.52 (s, 2 H); 7.35 – 7.42 (m, 2 H); 7.50 (t, 1 H, J = 8.0Hz); 7.73 (d, 1 H, J = 8.0Hz).

Step 2: Dissolve 3',4',5'-Trimethoxy-biphenyl-2-carboxylic acid methyl ester (55) (626mg, 2.08mmol) in MeOH (14mL) at rt and add 1M aqu LiOH (4.2mL, 4.20mmol). Stir reaction mixture for 8h under reflux. Remove solvent and partition the residue between 1M aqu. HCl and EtOAc, separate layers, extract the aqu. layer with EtOAc (3x), wash the combined organic layer with brine and dry with Na₂SO₄. Remove solvent and recrystallize residue from EtOAc/CyH 1+2 to obtain 3',4',5'-Trimethoxy-biphenyl-2-carboxylic acid (56) as a white solid (423mg, 79%). ¹H NMR (400MHz, CD₃OD: 3.84 (s, 3 H); 3.89 (s, 6 H); 6.68 (s, 2 H); 7.42 – 7.49 (m, 2 H); 7.57 (t, 1 H, J = 7.5Hz); 7.76 (d, 1 H, J = 8.0Hz).

Step 3: (The following reaction is done in an anhydrous N₂ atmosphere.) Dissolve 3',4',5'-Trimethoxy-biphenyl-2-carboxylic acid (56) (54mg, 0.18mmol) in anhydrous DCM (1.3mL) and add anhydrous DMF (1 drop, cat. amount). Then add slowly oxalyl chloride (21μL, 0.24mmol) by keeping temperature at ca. 20°C with a water bath and stir the turbid mixture for additional 2h at rt. Remove solvent and dry in vacuum to obtain crude 3',4',5'-Trimethoxy-biphenyl-2-carbonyl chloride (57) as a yellow solid. No further purification.

Step 4: Add a solution of 3',4',5'-Trimethoxy-biphenyl-2-carbonyl chloride (57) (0.18mmol) in DCM (1.0mL) to an ice cooled solution of [5-(2-Amino-phenyl)-thiophen-30-2-yl]-acetic acid methyl ester (36) (46mg, 0.18mmol) in anhydrous DCM (2.0mL) and anhydrous pyridine (0.5mL). Stir the reaction mixture for 1h at 0°C and additional 20h at

- 53 -

rt. Pour the reaction mixture into ice cooled 1M aqu. HCl, extract with EtOAc (2x) and DCM (2x), wash the combined organic layer with brine and dry with Na₂SO₄. Purify the crude product by preparative radial chromatography (silica gel, EtOAc/CyH 1+2) to obtain (5-{2-[(3',4',5'-Trimethoxy-biphenyl-2-carbonyl)-amino]-phenyl}-thiophen-2-yl)-acetic acid methyl ester (58) as a light brown solid (58mg, 59%). ¹H NMR (400MHz, CDCl₃): 3.70 (s, 3 H); 3.76 (s, 6 H); 3.78 (s, 2 H); 3.80 (s, 3 H); 6.29 (d, 1 H, *J* = 3.4Hz); 6.60 (s, 2 H); 6.75 (d, 1 H, *J* = 3.4Hz); 7.07 (t, 1 H, *J* = 7.6Hz); 7.23 (d, 1 H, *J* = 7.6Hz); 7.31 (t, 1 H, *J* = 8.0Hz); 7.37 –7.43 (m, 2 H); 7.48 (t, 1 H, *J* = 7.6Hz); 7.52 (s, 1 H); 7.69 (d, 1 H, *J* = 8.0Hz); 8.45 (d, 1 H, *J* = 8.0Hz).

10 **Step 5:** Dissolve (5-{2-[(3',4',5'-Trimethoxy-biphenyl-2-carbonyl)-amino]-phenyl}-thiophen-2-yl)-acetic acid methyl ester (58) (56mg, 0.11mmol) in MeCN (3.8mL) at rt and add 1M aqu LiOH (760μL, 0.76mmol). Stir reaction mixture 18h at rt. Quench reaction mixture (cooling bath) with 2M aqu. HCl. Extract the mixture with EtOAc (3x), wash the combined organic layer with brine and dry with Na₂SO₄ to obtain (5-{2-[(3',4',5'-Trimethoxy-biphenyl-2-carbonyl)-amino]-phenyl}-thiophen-2-yl)-acetic acid (59) (55mg, 99%) as a brown solid. ¹H NMR (400MHz, CDCl₃): 3.76 (s, 6 H), 3.80 (s, 3 H); 3.83 (s, 2 H); 6.32 (d, 1 H, *J* = 3.5Hz); 6.60 (s, 2 H); 6.78 (d, 1 H, *J* = 3.5Hz); 7.07 (t, 1 H, *J* = 7.6Hz); 7.23 (d, 1 H, *J* = 7.6Hz); 7.32 (t, 1 H, *J* = 7.6Hz); 7.36 – 7.54 (m, 3 H); 7.69 (d, 1 H, *J* = 8.0Hz); 8.43 (d, 1 H, *J* = 8.0Hz).


20

25

EXAMPLE 10

2',3',4'-Trimethoxy-biphenyl-3-carboxylic acid {2-[5-(1*H*-tetrazol-5-ylmethyl)-thiophen-2-yl]-phenyl}-amide (87)

SCHEME 17



- 5 **Step 1:** (The following reaction is done in an anhydrous N_2 atmosphere.) Dissolve nitrile (82) (500mg, 4.06mmol) in anhydrous DMF (2.7mL), cool to 0°C, add *N*-bromosuccinimide (795mg, 7.79mmol) in portions over a period of 20min and stir the mixture for 22h at rt. Partition the reaction solution between dichloromethane and water (1+1) and extract the separated aqueous layer 2 times with dichloromethane. Wash
10 combined organic layer with water and brine and dry with Na_2SO_4 . Remove solvent under reduced pressure and purify the crude product by preparative radial chromatography (silica gel 60PF, CyH/EtOAc 10+1] to obtain (5-bromo-thiophen-2-yl)-acetonitrile (83) as a light yellow liquid (745mg, 91%). [M. A. Ismail, R. Brun, J. D. Easterbrook, F. A. Tanious, W. D. Wilson, D. W. Boykin, *J. Med. Chem.* **2003**; *46* (22); 4761-4769]. 1H NMR (400MHz, $CDCl_3$): 3.81 (d, 2 H, J = 1.0 Hz); 6.81 (d, 1 H, J_1 = 3.8 Hz, J_2 = 1.0 Hz); 6.92 (d, 1 H, J = 3.8 Hz).

- 55 -

Step 2: (The following reaction is done in an oxygenfree N₂ atmosphere.) Dissolve tetrakis-(triphenylphosphine)-palladium(0) (29mg, 2.5mol%) and nitrile (83) (101mg, 0.50mmol) in DME (3.7mL). The reaction mixture is degassed 5 times and flooded with N₂ again. Add 2-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenylamine (84) (120mg, 0.55mmol), rinse with DME (0.5 mL), add aqu. 1M NaHCO₃, degas again (5 times) and stir the reaction solution 2h at 90°C (reflux). After cooling to rt partition the reaction mixture between EtOAc and brine (1+1) and extract the separated aqueous layer 3 times with EtOAc. Wash combined organic layer with brine and dry with Na₂SO₄. Remove solvent under reduced pressure and purify the crude product by preparative radial chromatography (silica gel 60PF, CyH/EtOAc 2+1) to obtain [5-(2-amino-phenyl)-thiophen-2-yl]-acetonitrile (85) as a brownish oil (84mg, 78%). ¹H NMR (400MHz, CDCl₃): 3.89 (br.s, 2 H); 5.20-6.50 (br.s, 2 H); 6.92 (t, 1 H; J = 7.6 Hz); 6.95-7.00 (m, 1 H); 6.99 (d, 1 H; J = 3.8 Hz); 7.11 (d, 1 H; J = 3.8 Hz); 7.21 (dd, 1 H; J₁ = 7.6 Hz, J₂ = 1.3 Hz); 7.27 (dd, 1 H; J₁ = 7.6 Hz, J₂ = 1.3 Hz).

Step 3: (The following reaction is done in an anhydrous N₂ atmosphere.) Add a solution of 2',3',4'-trimethoxy-biphenyl-3-carbonyl chloride (35) (117mg, 0.38mmol) in dichloromethane (1.3mL) to an ice cooled solution of the aniline (85) (82mg, 0.38mmol) in anhydrous dichloromethane (2.6mL) and anhydrous pyridine (0.65mL). Stir the reaction mixture for 1h at 0°C and additional 21h at rt. Pour the reaction mixture into ice cooled 1M aqu. HCl (20mL), extract with dichloromethane (2x) and EtOAc (1x), wash the combined organic layer with brine and dry with Na₂SO₄. Purify the crude product by preparative radial chromatography (silica gel 60PF, EtOAc/CyH 1+3 (incl. 2% MeOH), later 1+3) to obtain anilide (86) as an orange solid (132mg, 71%). ¹H NMR (400MHz, C₆D₆) 2.88 (d, 2 H, J = 1.0 Hz); 3.53 (s, 3 H); 3.55 (s, 3 H), 3.94 (s, 3 H), 6.63 (d, 1 H, J = 3.5 Hz); 6.64 (d, 1 H, J = 8.6 Hz); 6.66 (d, 1 H, J = 3.5 Hz); 6.99 (td, 1 H; J₁ = 7.6 Hz, J₂ = 1.0 Hz); 7.01 (d, 1 H, J = 8.6 Hz), 7.25-7.34 (m, 3 H); 7.74 (dt, 1 H; J₁ = 7.8 Hz, J₂ = 1.5 Hz); 7.97 (dt, 1 H, J₁ = 7.8 Hz, J₂ = 1.5 Hz), 8.18 (t, 1 H, J = 1.5 Hz), 8.34 (br. s, 1 H); 9.14 (d, 1 H, J = 7.8 Hz).

Step 4: (The following reaction is done in an anhydrous N₂ atmosphere.) Dissolve anilide (86) (60mg, 0.12mmol) in anhydrous DMF (2.0mL), add sodium azide (18mg, 0.14mmol) and ammonium chloride (9mg, 0.85mmol) and stir the reaction solution for 2d

at 90°C. Add again sodium azide (18mg, 0.14mmol) and ammonium chloride (9mg, 0.85mmol) and stir for additional 3d at 90°C. Cool mixture to rt and adjust pH=1 by addition of 1M HCl. Extract aqueous layer with dichloromethane (3x). Wash the combined organic layer with brine, dry with Na₂SO₄ and remove solvent under reduced pressure.


- 5 Purify the crude product by preparative radial chromatography (silica gel, EtOAc/CyH 1+2, later EtOAc/MeOH 9+1) to obtain 2',3',4'-trimethoxy-biphenyl-3-carboxylic acid {2-[5-(1H-tetrazol-5-ylmethyl)-thiophen-2-yl]-phenyl}-amide (87) as a yellow solid (50mg, 76%) [F. Osterod, L. Peters, A. Kraft, T. Sano, J. J. Morisson, N. Feeder, A. B. Holmes, *J. Mater. Chem.* **2001**, *11*, 1625-1633 and refer. therein. ¹H-NMR (400MHz, (CD₃)₂SO):
- 10 3.61 (s, 3 H); 3.80 (s, 3 H); 3.84 (s, 3 H); 4.45 (s, 2 H); 6.93 (d, 1 H; *J* = 8.6 Hz); 6.93 (d, 1 H; *J* = 3.5 Hz); 7.11 (d, 1 H, *J* = 8.6 Hz); 7.26 (d, 1 H, *J* = 3.5 Hz); 7.33 (td, 1 H, *J*₁ = 7.3 Hz, *J*₂ = 1.8 Hz); 7.35 (td, 1 H, *J*₁ = 7.3 Hz, *J*₂ = 1.8 Hz); 7.43-7.47 (m, 1 H); 7.53 (t, 1 H, *J* = 7.7 Hz); 7.61 (dd, 1 H, *J*₁ = 7.0 Hz, *J*₂ = 2.0 Hz); 7.66 (d, 1 H, *J* = 7.6 Hz); 7.85 (d, 1 H, *J* = 7.6 Hz); 7.99 (s, 1 H); 10.07 (s, 1 H).

15

EXAMPLE 11

2',3',4'-Trimethoxy-biphenyl-3-carboxylic acid (2-bromo-5-nitro-phenyl)-amide (89)

SCHEME 18



- (The following reaction is done in an anhydrous N₂ atmosphere.) Add a solution of 2',3',4'-trimethoxy-biphenyl-3-carbonyl chloride (35) (345mg, 1.13mmol) in dichloromethane (5mL) to an ice cooled solution of 2-bromo-5-nitro-phenylamine (88) (232mg, 1.07mmol) in anhydrous dichloromethane (12mL) and anhydrous pyridine (2.9mL). Stir the reaction mixture for 15min at 0°C and additional 17h at rt. Pour the reaction mixture into ice cooled


1M aqu. HCl (to get pH ca. 3), extract with EtOAc (3x), wash the combined organic layer with brine and dry it with Na₂SO₄ to afford crude 2',3',4'-trimethoxy-biphenyl-3-carboxylic acid (2-bromo-5-nitro-phenyl)-amide (89) as a beige solid (542mg, quant.). ¹H NMR (400MHz, CDCl₃): 3.72 (s, 3 H); 3.91 (s, 3 H); 3.93 (s, 3 H); 6.77 (d, 1 H, *J* = 8.6 Hz); 5 7.08 (d, 1 H, *J* = 8.6 Hz); 7.56 (t, 1 H, *J* = 8.8 Hz); 7.75 (d, 2 H, *J* = 8.8 Hz); 7.86 (d, 1 H, *J* = 8.8 Hz), 7.87 (d, 1 H, *J* = 8.8 Hz); 8.09 (t, 1 H, *J* = 1.7 Hz); 8.61 (br. s, 1 H); 9.59 (d, 1 H, *J* = 2.5 Hz).

EXAMPLE 12

10

N-(3-Nitro-phenyl)-3-(3,4,5-trimethoxy-phenyl)-propionamide (91)

SCHEME 19



15

(The following reaction is done in an anhydrous N₂ atmosphere.) Suspend EDC hydrochloride (402mg, 2.10mmol) and Et₃N (293μL, 2.10mmol) in anhydrous dichloromethane (17.0mL) and stir the resulting solution for 5min at rt. Add 3-(3,4,5-trimethoxy-phenyl)-propionic acid (481mg, 2.00mmol) and DMAP (24mg, 0.20mmol) and stir the resulting solution for 5min. Add 3-nitro-phenylamine (90) (414mg, 3.00mmol) and stir the reaction solution 24h at rt. Quench reaction solution with sat. aqu. NH₄Cl and water, separate layers and extract aqu. layer with EtOAc (3 times). Wash the combined organic layer with water and brine and dry with Na₂SO₄. Purify the crude product by preparative radial chromatography (silica gel 60PF, EtOAc/CyH 1+1) to obtain *N*-(3-nitro-phenyl)-3-(3,4,5-trimethoxy-phenyl)-propionamide (91) (508mg, 70%) as a yellowish solid. ¹H NMR (400MHz, CDCl₃): 2.65 (t, 2 H, *J* = 7.3 Hz); 2.98 (t, 2 H, *J* = 7.3 Hz); 3.79


- 58 -

(s, 6 H); 3.81 (s, 3 H), 6.42 (s, 2 H); 7.41 (s, 1 H); 7.45 (t, 1 H, $J = 8.0$ Hz); 7.84 (d, 1 H, $J = 8.0$ Hz); 7.92 (d, 1 H, $J = 8.0$ Hz); 8.31 (s, 1 H).

The compounds referred to in the following SCHEME 16 are those compounds referred to
5 as the particularly preferred compounds herein.

- 59 -

SCHEME 16



Sialyl Lewis^X Tyrosine Sulfate Assay (sLe^X TSA):

Compounds of the present invention are assayed on a molecular level for their ability to inhibit the binding of P-, L-, or E-selectin chimeric molecules to sLe^X and tyrosinesulfate residues linked to a polymeric matrix as a PSGL-1 substitute. IC₅₀-values are determined.

- 5 Microtiter plates are coated overnight in carbonate buffer pH9,6 with goat anti human Fc mAB (10 µg/ml). After washing in assay buffer (25mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 150mM NaCl, 1mM CaCl₂ pH7,4) and blocking (3% bovine serum albumin (BSA) in assay buffer) plates are incubated for 2h at 37°C with human P-Selectin-IgG-chimera (0,61nM respectively 150ng/mL) or human L-Selectin-
10 IgG-chimera (0,61nM respectively 89ng/mL) or human E-Selectin-IgG-chimera (0,61nM respectively 131ng/mL). 5µl of sLe^X -tyrosine sulfate polyacrylamide (1mg/ml) carrying 15% sLe^X, 10% Tyrosine-sulfate and 5% biotin is complexed with 20µl Streptavidin-Peroxidase solution (1mg/ml) and 25µl assay buffer without CaCl₂. For use in the assay, the ligand complex is diluted 1:10000 in assay buffer and further diluted 1:1 with varying
15 amounts of compounds in assay buffer incl. 2%DMSO. This mixture is added to the wells precoated with E- or P-selectin. After incubation for 2h at 37°C, wells are washed for six times with in assay buffer incl. 0,005% Polyoxyethylenesorbitan monolaurate (TWEEN 20), developed for 10-15min with 20µl 3,3',5,5'-tetramethylbenzidine (TMB)/H₂O₂ substrate solution and stopped with 20µl 1M H₂SO₄. Bound sLe^X -Tyrosine sulfate ligand
20 complex is determined by measuring optical density at 450nm vs. 620nm in a Fusion alpha-FP reader (sold from Packard Bioscience, Dreieich, Germany).

Results from sLe^XTSA: IC₅₀ Data for E-/ P-/ L-Selectin

Compound	IC ₅₀ E-Selectin [µM]	IC ₅₀ P-Selectin [µM]	IC ₅₀ L-Selectin [µM]
Bimosiamose	>500	95.0	>500
60	18.2	15.0	12.8
61	>500	186.1	385.3
62	74.7	46.4	45.3
63	>500	28.5	76.1
64	>500	107.1	382.9

Results from sLe^xTSA: IC₅₀ Data for E-/ P-/ L-Selectin

Compound	IC ₅₀ E-Selectin [μM]	IC ₅₀ P-Selectin [μM]	IC ₅₀ L-Selectin [μM]
87	-	32.6	59.5

Flow Chamber Assay / Cell Adhesion and Rolling under Flow Conditions

- 5 To assess the capability of compounds to inhibit cell binding under dynamic conditions resembling the flow in a blood vessel, flow chamber assays addressing/ testing binding of HL-60 cells / various cell lines to P-selectin, L-selectin and E-selectin chimeric molecules are performed.
- 10 Cell attachment under flow conditions are determined using a parallel flow chamber system. A 35mm polystyrene culture dish is coated for 1 hour at room temperature with coating buffer (50mM tris-(hydroxymethyl) aminomethane buffer (Tris), 150 mM NaCl, 2 mM CaCl₂; pH 7,4) containing human E- or P-selectin-IgG chimera at concentrations of 2,5μg/ml or 10μg/ml, respectively. After removal of the coating solution non specific binding sites are blocked for an additional hour with 1% BSA in coating buffer at room
- 15 temperature. After washing with assay buffer ("Roswell Park Memorial Institute 1640" (RPMI 1640) + 10mM HEPES) the dish is fitted into a parallel plate laminar flow chamber (sold from Glycotech, Rockville, MD) and mounted on an inverted phase-contrast microscope (sold from Olympus, Hamburg, Germany) equipped with a CCD camera (JVC) that is connected to a PC. Employing a peristaltic pump (sold from Ismatec, Wertheim-Mondfeld, Germany) the re-circulating system is equilibrated with assay buffer containing
- 20 125μM compound or vehicle control (DMSO). Cells (1 million / ml) are added to the chamber and allowed to distribute for 2 minutes at a high flow rate. The flow rate is then decreased resulting in a calculated flow shear of 1 dyne/cm². Video sequences of 10 low power fields are digitally recorded after 5 minutes continuous flow. The percentage of
- 25 modulation is calculated from the mean number of cells per field that attached to the coated dish surface in the presence versus absence of compound of at independent experiments.

Data from Flow Chamber Assay for E- and P-Selectin

Values are given as normalized ratios of %-inhibition of compound x divided by %-inhibition of bimosiamose.



5 MJ

Compound	E-Selectin [Ratio]	P-Selectin [Ratio]
63	1.46	1.06
64	1.27	1.01

Compound	E-Selectin [Ratio]	P-Selectin [Ratio]
87	1.23	2.62

Claims

1. Pharmaceutical compositions comprising at least one compound of the formulas (Ia) or (Ib) and a pharmaceutically acceptable carrier which is useful in a medicine,




5

wherein the symbols, indices and substituents have the following meaning

-X- =


(a)



10




with m = 0,1; n = an integer from 1 to 3

(b)



15


wherein "ring" is



- 64 -

and with R¹ being H, NO₂, CF₃, F, Cl, Br, I, CN, CH₃, NH₂, NHAlkyl, NHArlyl, NHAcyl and k = 0,1


(c)



5 T being O, S or [H,H]; p = 0,1,2,

-Y =

(a)



with s being 0 or 1,

10 R² being CO₂H, CO₂Alkyl, CO₂Aryl, CO₂NH₂, CO₂Aralkyl, SO₃H, SO₂NH₂, PO(OH)₂, 1-H-tetrazolyl-, CHO, COCH₃, CH₂OH, NH₂, NHAlkyl, N(Alkyl)Alkyl', OCH₃, CH₂OCH₃, SH, F, Cl, Br, I, CH₃, CH₂CH₃, CN, CF₃

R³ independently from R² being H, CH₃, CH₂CH₃, CF₃, F, Cl, Br, I, CN, NO₂ and


15 R⁴ independently from R² and R³ being H, CH₃, CH₂CH₃, CF₃, F, Cl, Br, I, CN, NO₂, R²

R⁵ being H, NO₂, CF₃, F, Cl, Br, I, CN, CH₃, OCH₃, SH, NH₂

and -W- = -(CH₂-)_v, cis-CH=CH- or trans-CH=CH-, and v being 0,1,2;

in case that -W- is cis-CH=CH- or trans-CH=CH-, R² must not be NH₂ or SH;

(e)




20

with t being 0,1,2

- 65 -

-Z =

(i)



R⁷ independently from R² being H, NO₂, CF₃, F, Cl, Br, I, CN, CH₃, OCH₃, SH,

5 NH₂,

(iv)




with K = NH, NMe, O, S

10

or the pharmaceutically acceptable salts, esters or amides and prodrugs of the above identified compounds of formulas (Ia) or (Ib).

2. Pharmaceutical compositions according to claim 1, wherein the compounds are
15 defined by formulas (IIa) or (IIb)







wherein -Y is as defined as in claim 1 and -X'- is X (b) or X (c).


20

3. Pharmaceutical compositions according to claim 1, wherein the compounds are defined by formulas (A1), (B1), (A2) or (B2)

- 66 -




5 wherein -X'- and -Y are as defined in claim 2 and wherein -X''- is





and wherein -Y' is

10





wherein all indices, symbols and substituents are as defined above.

4. Pharmaceutical compositions according to claim 3, wherein the compounds are defined by formulas (C) or (D)





5 wherein -X''- and -Y' are as defined in claim 3.

5. Pharmaceutical compositions according to claim 4, wherein the compounds are defined by formulas (E) or (F)



wherein -X''- is as defined in claim 3 and -Y''- is



with R⁹ being CO₂H, CO₂alkyl, CO₂aryl, CO₂NH₂, CO₂aralkyl, CH₂SO₃H, CH₂SO₂NH₂, CH₂PO(OH)₂, 1-H-tetrazolyl, CHO, COCH₃, CH₂OH, CH₂NH₂, CH₂NHalkyl, CH₂N(alkyl)alkyl', CH₂OCH₃, CH₂SH,
wherein all indices, symbols and substituents are as defined in claim 1.

6. Chemical compounds having the general structure of formula (C) or (D) or (E) or (F) according to claim 4 or 5.
7. Use of compounds having the structure of formulas (Ia) or (Ib) as defined in claim 1 for the preparation of a medicine for the treatment of Chronic Obstructive Pulmonary Disease (COPD), acute lung injury (ALI), cardiopulmonary bypass, acute respiratory distress syndrome (ARDS), Crohn's disease, septic shock, sepsis, chronic inflammatory diseases such as psoriasis, atopic dermatitis, and rheumatoid arthritis, and reperfusion injury that occurs following heart attacks, strokes, atherosclerosis, and organ transplants, traumatic shock, multi-organ failure, autoimmune diseases like multiple sclerosis, percutaneous transluminal angioplasty, asthma and inflammatory bowel disease.
10
8. Use of compounds having the structure of formulas (C) or (D) as defined in claim 4 for the preparation of a medicine for the treatment of Chronic Obstructive Pulmonary Disease (COPD), acute lung injury (ALI), cardiopulmonary bypass, acute respiratory distress syndrome (ARDS), Crohn's disease, septic shock, sepsis, chronic inflammatory diseases such as psoriasis, atopic dermatitis, and rheumatoid arthritis, and reperfusion injury that occurs following heart attacks, strokes, atherosclerosis, and organ transplants, traumatic shock, multi-organ failure, autoimmune diseases like multiple sclerosis, percutaneous transluminal angioplasty, asthma and inflammatory bowel disease.
15
9. Use of compounds having the structure of formulas (Ia) or (Ib) as defined in claim 1 for the preparation of a medicine for the treatment, diagnosis or prophylaxis of inflammatory disorders.
20
10. Use of compounds having the structure of formulas (Ia) or (Ib) as defined in claim 1 for the preparation of a vehicle for drug targeting of diagnostics or therapeutics.
30
11. Use of compounds having the structure of formulas (Ia) or (Ib) as defined in claim 1 for the preparation of a cosmetic or dermatological composition.

- 69 -

12. Cosmetic compositions comprising at least one compound of the formulas (Ia) or (Ib) as in claim 1 and at least one cosmetically tolerable component.
13. Dermatological compositions comprising at least one compound of formulas (Ia) or (Ib) as in claim 1 and at least one dermatologically tolerable component.
5

10

15

20

25

30

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2006/009154

A. CLASSIFICATION OF SUBJECT MATTER
INV. A61K31/05 A61P11/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2003/187306 A1 (SINHA ARUN KUMAR ET AL) 2 October 2003 (2003-10-02) *cf. page 1, section [0001], claims* -----	1-10
Y	WO 99/29705 A (GLYCOMED INCORPORATED; SANKYO CO., LTD; ANDERSON, MARK, B; KOBAYASHI,) 17 June 1999 (1999-06-17) *cf. abstract, page 10, line 11 to page 11, first para., page 12, line 19 bridging with page 13, line 16* -----	1-10
Y	WO 03/075905 A (BOBEL 246, S.L; LOPEZ-BELMONTE PASCUAL, JESUS; LOPEZ-BELMONTE PASCUAL,) 18 September 2003 (2003-09-18) *cf. abstract, page 3, line 29 extending to page 4, line 11* ----- -/-	1-10

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

6 March 2007

Date of mailing of the international search report

13/03/2007

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Stoltner, Anton

INTERNATIONAL SEARCH REPORT

International application No PCT/EP2006/009154

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 217 204 A (MERCK & CO. INC) 8 April 1987 (1987-04-08) *cf. abstract, example 3 on col. 24, claim 1* -----	1-10
Y	EP 0 465 122 A (MERCK & CO. INC) 8 January 1992 (1992-01-08) *cf. abstract, page 2, lines 1-22, claim 1* -----	1-10
Y	US 4 363 813 A (KAWASAKI ET AL) 14 December 1982 (1982-12-14) *cf. abstract, col. 1, lines 1-53* -----	1-10

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP2006/009154

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210

3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-10

Pharmaceutical compositions, chemical compounds comprising trimethoxy phenyl subunits and the use thereof in the diagnosis and medical treatment.

2. claims: 11-13

The use of trimethoxy phenylic compounds for the preparation of cosmetic and dermatological purposes.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box II.2

Claims Nos.:

Present claim 9 relates to an undefined number of possible pathological conditions falling into the term "inflammatory disorders". However, the description does not provide support and disclosure in the sense of Article 6 and 5 PCT for any such inflammatory disorders and there is no common general knowledge of this kind available to the person skilled in the art. This non-compliance with the substantive provisions is to such an extent, that the search was performed taking into consideration the non-compliance in determining the extent of the search of the claim (PCT Guidelines 9.19 and 9.20).

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

INTERNATIONAL SEARCH REPORT

Information on patent family members

 International application No
PCT/EP2006/009154

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
US 2003187306	A1	02-10-2003	WO	03080551 A1		02-10-2003
WO 9929705	A	17-06-1999	AU	1804299 A		28-06-1999
WO 03075905	A	18-09-2003	AU	2002246135 A1		22-09-2003
EP 0217204	A	08-04-1987	DK	437286 A		14-03-1987
			ES	2002312 A6		01-08-1988
			JP	62067081 A		26-03-1987
EP 0465122	A	08-01-1992	CA	2045863 A1		30-12-1991
			JP	5092963 A		16-04-1993
			JP	7017627 B		01-03-1995
US 4363813	A	14-12-1982	CA	1150272 A1		19-07-1983
			DE	3026054 A1		05-02-1981
			ES	8105987 A1		16-09-1981
			ES	8201565 A1		16-03-1982
			FR	2465729 A1		27-03-1981
			GB	2056440 A		18-03-1981
			IT	1131682 B		25-06-1986